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Cardiac contraction and relaxation depend on intracellular Ca2+ release and sequestration in 
the sarcoplasmic reticulum (SR). The small tail-anchored protein phospholamban (PLN) is 
essential for normal stress-adaptation of heart function. The dephosphorylated PLN form binds 
to the Ca2+ ATPase SERCA2a and potentially to other important SER proteins and thereby 
regulates the reuptake of Ca2+ into the SR. To elucidate the PLN associated signalosome in 
endogenous SR domains, we developed a PLN-specific proximity assay and applied 
complexome profiling on native cardiac membranes. 
 
Here, a mass spectrometry-based method described as complexome profiling, originally 
established to identify OXPHOS protein supercomplexes and assembly factors, is used to 
elucidate the composition of essential protein complexes important for the intracellular Ca2+ 
cycling in ventricular cardiomyocytes. Digitonin solubilized, enriched membrane fractions of 
isolated ventricular cardiomyocytes from wildtype and phospholamban knockout mice were 
loaded and separated by blue native gradient gel electrophoresis (BN-PAGE). Gel lanes were 
cut, and trypsin digested followed by mass spectrometry (LC-MS/MS). 
Hierarchical clustering and analysis of migration patterns confirmed distinct groups of co-
migrating proteins, most prominently OXPHOS complexes, which were used for quantitative 
validation. Importantly, at higher molecular weight, a novel SR Ca2+ cycling complex comprised 
of the RyR2 calcium release channel, SERCA2a, and each regulatory protein subunits were 
identified. Furthermore, the sarcolemmal membrane-associated protein (SLMAP) was 
identified as a potential interacting protein of PLN.  
Combined with phospholamban knockout, complexome profiling enabled the close-to-native 
analysis of previously unknown macromolecular protein complexes comprised of dual RyR2-
SERCA2a transporters, changes in abundance due to phospholamban deficiency. 
 
Additionally, for proteomic mapping, APEX2, a genetically engineered peroxidase, was fused 
N-terminally to generate APEX2-PLN. Adenoviral expression and biotin-phenol treatment were 
used to label proteins in nanometric proximity of PLN by biotinylation in living neonatal rat 
cardiomyocytes (NRCMs). APEX2-biotinylated proteins were enriched by pulldown, 
processed, and analyzed by mass spectrometry (LC-MS/MS). Additionally, for ratiometric 
analysis, NRCMs were cultivated with stable isotope labeled amino acids (SILAC). A truncated 
APEX2-PLNΔ(1-29) construct was used as SR-targeted control and enhanced green 
fluorescent protein (eGFP) as a negative control. 
APEX2-PLN expression in NRCMs was confirmed by Western blot (WB) and fluorescence 
microscopy through the bicistronically expressed eGFP. Confocal analysis showed that 
XVII 
 
APEX2-PLN co-localizes with endogenous SERCA2a similar to endogenous PLN. The 
medium and heavy labeled amino acids (SILAC) were incorporated at a rate of >95%, thus 
enabling global quantitative proteomic analysis. 14-3-3 proteins were identified as significantly 
enriched gene family for APEX2-PLN biotinylation. 
A PLN-specific strategy for proximity labeling was successfully developed in live NRCM and 
verified for known interaction partners. Proteomic proximity analysis identified previously 
unknown PLN protein-protein interactions in the neonatal heart. Furthermore, these potential 






Calcium (Ca2+) is a universal second messenger and involved in diverse cellular processes 
and signaling pathways1. In the heart, Ca2+ plays a central role in cardiomyocyte excitation, 
contraction, and relaxation2. An increase of the cytosolic Ca2+ concentration leads to the 
activation of the contraction apparatus, whereas its deceleration initiates the relaxation phase. 
Upon depolarization of the plasma membrane, Ca2+ enters the cytosol through L-type Ca2+ 
channels (dihydropyridine receptors; DHPRs). The increased local Ca2+ concentration 
stimulates the opening of Ca2+ release channels (Ryanodine receptors; RyR) and the release 
of Ca2+ from the sarcoplasmic reticulum (SR). The increased cytosolic Ca2+ concentration 
leads to troponin C binding and the activation of muscle contraction. The relaxation phase is 
initiated by the removal of Ca2+ from the cytosol by plasma-membrane Ca2+-ATPases (PMCAs) 
or Na+/Ca2+ exchangers (NCXs), which are located in the plasma membrane, or by the 
sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a), located in the SR. More than 70% 
of the Ca2+ removal from the cytosol is through SERCA2a. Its activity is determined by the 
regulatory protein phospholamban (PLN), which in turn is regulated through the ß-adrenergic 
signaling pathway. Dephosphorylated PLN inhibits SERCA2a activity, while its 
phosphorylation by PKA or CamK2 releases the inhibitory effect. Hence, SERCA2a determines 
not only the rate of Ca2+ removal but also the size of the Ca2+ store in the SR increasing the 
contractility proportional3. This makes SERCA2a a key protein and regulator of muscle 
contractility. 
 
1.1 SERCA2a: Sarco/endoplasmic reticulum Ca+2 ATPase 2a 
SERCA belongs similar to the Na,K-ATPase and the H,K-ATPase to the family of P-type 
ATPases, which are highly conserved in structure4. The SERCA family includes several 
isoforms, which are encoded by three homologous genes SERCA1, SERCA2, and SERCA3 
(Table 1)5. The gene of SERCA1 encodes for two isoforms by alternative splicing, SERCA1a 
and SERCA1b. They represent the adult and fetal isoform in fast-twitch skeletal muscle, 
respectively6. The SERCA2 gene encodes for a transcript that gives rise to three different 
isoforms by alternative splicing: SERCA2a, SERCA2b, and SERCA2c. SERCA2a and 
SERCA2b are mainly expressed in slow-twitch skeletal muscle cells and cardiac muscle cells, 
while SERCA2c has been detected in epithelial, mesenchymal and hematopoietic cell lines7,6 
as well as in cardiac muscle8. SERCA3 gives at protein level rise to isoform 3a, 3b, and 3c and 





Table 1 Distribution of SERCA isoforms in mammalian tissue  
 Skeletal muscle      
 Fast twitch  Slow twitch  Cardiac muscle Smooth 
muscle 
Non-muscle 
cells SERCA isoform Fetal Adult  Fetal Adult  Fetal Adult 
SERCA1a - +++++  - -  - - - - 
SERCA1b +++ -  - -  - - - - 
SERCA2a + -  + +++  + ++++ + - 
SERCA2b + +  + +  + + + + 
SERCA2c        +  + 
SERCA3a - -  - -  - - - + 
SERCA3b - -  - -  - - - + 
SERCA3c - -  - -  - - - + 
(adapted from Periasamy et al.)4 
 
Based on the crystal structure of SERCA1a, Ca2+ transport is well described11,12,13. Recently 
the first crystal structure of SERCA2a has been resolved, showing high similarity to SERCA1a, 
which indicates a conserved mechanism14. In general, SERCA is composed of three 
cytoplasmic domains, namely the nucleotide binding domain (N), the phosphorylation domain 
(P), the actuator domain (A), and one transmembrane domain (M) (Figure 1). 
The N-domain contains the binding site for adenosine triphosphate (ATP). In SERCA1 and 
SERCA2, but not in SERCA3, an interaction site for the reversible inhibitor phospholamban is 
located in the N-domain. The P-domain is the functional core of the SR Ca2+-ATPase and 
contains the sequence motive DKTGTLT in which D is the reversibly phosphorylated 
asparagine (Asp351). This sequence is conserved in all P-type ATPases15. The A-domain 
facilitates the conformational change for Ca2+ transport. The M-domain is composed of ten 
membrane-spanning helices (M1-M10) and is the least conserved domain amongst P-type 
ATPases with a sequence homology of 18%. It contains the Ca2+ translocation site, which is 
coordinated by the polar and ionic side chains of the transmembrane helices M4, M5, M6, and 
M8 and allows the localization of two bound Ca2+ ions16. They are centrally located and 
surrounded on the one side by M1-3 on the opposite side by M8-10. M6 and M7 are separated 
by a long cytosolic loop, which mediates the interaction of the P and M-domain and forms 





Figure 1 SR Ca2+ ATPase domains 
The SR Ca2+ ATPase consists of three cytosolic and one transmembrane domain. The nucleotide 
binding (N)-domain is shown in red, the phosphorylation (P)-domain in blue, the actuator (A)-domain in 
yellow, and the membrane (M)-domain in grey. Through the binding of two Ca2+ ions within the M-
domain and ATP binding to the N-domain, the resulting phosphorylation of Asp351 in the P-domain 
initiates a conformational change and the release of Ca2+ into the SR lumen.  
 
The reaction of ATP-binding, hydrolysis and phosphorylation of the P-domain and the energy 
transfer to the  ion binding site is mostly the same in all P-type ATPases17. The extrusion of 
Ca2+ from the cytosol is facilitated by SERCA and initiates the muscle relaxation phase. The 
mechanistic transport of two Ca2+ ions per cycle is described at different conformational stages 
(Figure 2). In the E1 state, SERCA can bind two Ca2+ ions to its high-affinity binding site in the 
M-domain, which is accessible from the cytosol (2 Ca2+-E1-ATP). Through ATP binding to the 
N-domain, the two Ca2+ ions are retained and occluded within the protein. As a result, the 
Asp351 within the P-domain can be phosphorylated by the transfer of the γ-phosphate from 
ATP (2 Ca2+-E1~P). At this state, the phosphoryl group can still be transferred back to the 
ADP. From this intermediate stage, it gets into a low Ca2+ affinity and ADP insensitive stage 2 
Ca2+-E2-P. In the rate-limiting transition from E1-P to E2-P, the P-domain reorientates together 
with the A-domain rotation towards the phosphorylation site and protects the phosphoryl-group 
from hydrolysis, and ADP dissociation. This rate limiting transition is accompanied by the 
disruption of the high affinity Ca2+ binding site and the release of Ca2+ into the SR lumen. The 
phosphorylated Asp351 is now accessible for the hydrolysis of the E2-P. Inorganic phosphate 











Figure 2 Scheme of the E1/E2 model for SERCA  
Detailed explanation in the text. Scheme adapted from Wuytack et al.15 
 
In the heart, SERCA2a controls the rate of Ca2+ transport into the SR and the SR Ca2+ load, 
which determines the relaxation and contraction of a myocyte, respectively19. 
Studies in genetically defined models elucidated the role of SERCA2a in Ca2+ homeostasis 
and cardiac contractility. Transgene mice overexpressing SERCA2a showed increased Ca2+ 
transport and enhanced contractility and relaxation20,21,22. No cardiac pathology was observed, 
suggesting toleration of the overexpressed SERCA2a. In contrast, with SERCA2a-deficiency, 
mice were not viable23. A heterozygous null SERCA2a mouse showed a 35% reduced 
SERCA2a protein expression but no cardiac pathology24. But under challenging conditions, 
heterozygous mice showed in a heart failure model with induced ventricular hypertrophy 
impaired intracellular Ca2+ homeostasis and decreased rates of cardiac contractility25. This 
suggests the necessity of two functional SERCA2a gene copies for normal heart function. 
 
1.2 Phospholamban  
Phospholamban (PLN) is a small 52 amino acids long tail-anchored membrane protein, which 
is mainly expressed in the heart26. It was discovered as 22000 Dalton protein when SR vesicles 
isolated from heart muscle showed increased calcium uptake after the addition of cyclic 
adenosine monophosphate (cAMP) and protein kinase A (PKA) 27. This was related to the 
stimulatory effect mediated by the phosphorylation of PLN, which is colocalized with SERCA2a 
in SR membranes28. The analysis of Ca2+ kinetics demonstrated that dephosphorylated PLN 
diminishes the apparent affinity of SERCA2a for Ca2+. 29  
PLN is present in two different physiological states and forms monomers and pentamers. The 
active dephosphorylated form is a substantial fraction of the monomer that binds to and inhibits 
SERCA2a. The pentameric PLNs are mainly phosphorylated and are thought to be inactive or 
less active than monomeric PLN30. Pentameric PLN can bind to SERCA2a as well and is 
2 Ca2+
2 Ca2+






SR lumen2 Ca2+P H2O
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suggested to be the preferred target of PKA phosphorylation, attenuating the monomeric 
phosphorylation and prolongs the interaction of PLN monomers with SERCA2a31. 
 
The amino acid sequence of PLN shows a high degree of homology for various tissues and 
species (Figure 3), and the gene was mapped to human chromosome 632.  
 
 
Figure 3 PLN sequence homology for various species 
Primary PLN amino acid sequence showing conserved sequence homology across species. Red 
marked amino acids show the sequence variation. The underlined sequence presents the PLN 
transmembrane domain for all species. 
 
The PLN protein has an alpha-helical structure that contains two major domains, the 
hydrophilic domain I with three phosphorylation sites at serine 10 (Ser10), serine 16 (Ser16) 
and threonine 17 (Thr17), and a hydrophobic domain II anchored to the SR membrane (Figure 
4). 
 
Figure 4 Modeling of PLN 
A, PLN contains three domains: cytosolic domain Ia containing the three phosphorylation sites Ser10, 
Ser16 and Thr17, cytosolic Ib, and the transmembrane domain II. B, PLN interacts with SERCA2a and 
reduces its affinity for Ca2+. Phosphorylated PLN cannot bind SERCA2a and activates the Ca2+-ATPase. 
Phosphorylation favors the pentameric assembly of PLN and serves as a pool for SERCA2a inhibition. 
 
Homo sapiens MEKVQYLTRS AIRRASTIEM PQQARQKLQN LFINFCLILI CLLLICIIVM LL
Mus musculus MEKVQYLTRS AIRRASTIEM PQQARQNLQN LFINFCLILI CLLLICIIVM LL
Rattus norvegicus MEKVQYLTRS AIRRASTIEM PQQARQNLQN LFINFCLILI CLLLICIIVM LL 
Oryctolagus cuniculus MEKVQYLTRS AIRRASTIEM PQQARQNLQN LFINFCLILI CLLLICIIVM LL
Canis familiaris MDKVQYLTRS AIRRASTIEM PQQARQNLQN LFINFCLILI CLLLICIIVM LL 
Sus scrofa MDKVQYLTRS AIRRASTIEM PQQARQNLQN LFINFCLILI CLLLICIIVM LL






















The cytosolic domain I is further divided into domain Ia (aa 1-20) and Ib (aa 21-30). Domain Ia 
consists of an alpha-helix and contains the phosphorylation sites, domain Ib is suggested to be 
relatively unstructured33. Domain II (aa 31-52) forms an alpha-helix in the SR membrane 
(Figure 4). This domain II contains leucine and isoleucine residues, building an essential 
leucine-zipper motif for the pentamer assembly33. PLN pentamers are SDS resistant, and only 
the increase of detergent concentrations and boiling dissociates them into monomers. In 
immunoblotting, the PLN monomer shows a molecular weight of 6.1 kDa and the pentamer of 
22 kDa34. 
 
1.3 PLN phosphorylation 
The region of PLN interacting with SERCA2a may involve amino acids 2 to 18. This association 
is disrupted by phosphorylation of Ser10, Ser16, or Thr17 in PLN by the cAMP dependent 
protein kinase C (PKC), the cAMP dependent protein kinase A (PKA) or Ca2+-calmodulin-
dependent protein kinase (CaMKII), respectively. This is due to the positive charge of the PLN 
cytosolic domain, and is partially neutralized by the phosphate group in these sites. 
Phosphorylation of PLN by the cAMP dependent protein kinase at Ser16 is associated with a 
local twist of the alpha-helix at positions 12 to 16, resulting in conformation changes in the 
recognition unit of the protein. Also, domain II affect the Ca2+ ATPase activity by lowering its 
affinity for Ca2+.33 
Prevention of Ser16 phosphorylation by mutagenesis (Ser16Ala) resulted in a reduced 
response to ß-adrenergic stimulation in a mouse model35. At the same, no phosphorylated 
Thr17 could be detected. Animals with the Thr17 substitution for alanine, Ser16 
phosphorylation was reactive for ß-adrenergic stimulation. Maximum inhibition of SERCA2a 
was observed in mice overexpressing this PLN forms35. 
The cAMP-dependent phosphorylation of PLN activates the SR Ca2+ by SERCA2a dissociation 
and contributes to the relaxation phase. The resulting increased Ca2+ levels accumulated by 
the SR would, in turn, lead to higher Ca2+ levels for the release from the SR during the 
contraction by binding to the contractile proteins. The critical role of PLN in the facilitation of ß-
adrenergic stimulation responses was shown in PLN-deficient mice36. The treatment of these 
cardiomyocytes showed an attenuated response to ß-adrenergic stimulation, indicating that 
PLN is a key target of this pathway. Also, other cardiac phosphoproteins like L-type Ca2+-
channel and phospholemman (PLM) in the sarcolemma, troponin I and troponin C-proteins in 
the myofilaments and the Ca2+ release channel RyR2 have been shown to contribute to the 
stimulatory effects of ß-adrenergic stimulation in the heart. 
Compared to PLN-deficient mice, transgenic mice that overexpress PLN by 2-fold and 4-fold 
in the heart showed decreased rates of contraction and relaxation. These increased inhibitory 
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effects were abolished by ß-adrenergic stimulation with the ß-agonist, which resulted in PLN 
phosphorylation and the relived inhibitory effects on SERCA2a37. Interestingly, mice with 4-
fold higher PLN protein expression showed elevated levels of adrenaline and noradrenaline, 
suggesting a compensatory adaption, which would enhance the phosphorylation of PLN and 
the activation of SERCA2a. 
 
1.4 PLN dephosphorylation by PP1 
The main phosphatase dephosphorylating PLN is the protein phosphatase 1 (PP1). This 
enzyme accounts for 70% of PLN phosphatase activity towards the PKA phosphorylation site 
Ser16 and CamK2 phosphorylation site Thr1738. The PP1 activity is significantly increased 
during human heart failure39. Its overexpression in mice to a level similar to failing human 
hearts resulted in depressed contractility and diminished response to ß-adrenergic stimulation, 
which resulted in hypertrophy, heart failure, and early death40. 
PP1 is a holoenzyme containing the catalytic domain, including its phosphatase activity and a 
regulatory subunit, which targets the PP1 to different subcellular locations41. Its endogenous 
inhibitor I-1 and I-2 additionally regulate PP1 activity. I-1 gets activated on phosphorylation at 
Thr35 PKA resulting in an attenuated PP1 activity. Constitutively active I-2 showed in a 
cardiac-specific mouse model depressed PP1 activity, increased Ca2+ transients, and 
enhanced contractile parameters42. Additionally, increased PLN phosphorylation at Ser16 but 
not at Thr17 was found, suggesting a site-specific preference of PP1 for PLN. Therefore, PP1 
is through PLN a crucial negative regulator of cardiac function. 
Furthermore, it has been suggested that the heat shock protein 20 (Hsp20/HSPB6) regulates 
cardiac contraction via the regulation of PP1 and PLN43. Interestingly, cardiac overexpression 
of Hsp20 showed enhanced contractility43, whereas the knockdown of Hsp20 by microRNA-
320 showed depressed contractility44. These data suggest that Hsp20 directly binds to PP1 
and inhibit its activity. As a direct consequence, PLN showed enhanced phosphorylation along 
with reduced PP1 protein expression in Hsp20 transgenic mice. Also, the increase of Hsp20 
levels preserved contractile parameters and was suggested to be cardio protective43. 
Additionally, the HS-1 associated protein X-1 (HAX-1) is described as a direct interaction 
partner of PLN45. The proposed minimal binding region is from amino acids 16 to 22, which 
includes the phosphorylation sides of PLN Ser16 and Thr17. It has been suggested that the 
binding between PLN and HAX-1  may control  PLN activity45. Similar to the PLN/SERCA2a 
binding, the interaction with HAX-1 is diminished upon PLN phosphorylation.  
Together these results support the beneficial effects of PLN phosphorylation and its regulation 




1.5 PLN mutations 
Several human mutations in the PLN gene have been identified to date. Two of these mutations 
are associated with increases in PLN inhibition of SERCA2, lowering its affinity for Ca2+. This 
is partially explained by the decreased phosphorylation of PLN by a cAMP-dependent protein 
kinase, preventing the release from SERCA2a. This chronic inhibition of SERCA2a by i.e. PLN 
mutation R14del or R9C leads to dilated cardiomyopathy (DCM) and premature death in 
families carrying this mutations46,47. The same phenotype was also found in transgenic mouse 
models carrying this mutations46,47. It is suggested that the endogenous PLNR14del mutant 
fails to co-localize with SERCA2a, resulting in enhanced contractility in mice due to sustained  
SERCA2a activity47. PLNR14del protein was shown to miss localize to the sarcolemma, where 
it interacts with Na,K-ATPase, and causes additional cardiac remodeling. 
 
1.6 PLN/SERCA in heart failure 
In human and experimental heart failure in mice, the protein level and the activity of SERCA2a 
were found to be decreased, contributing to failing cardiac conditions48,49. Furthermore, the 
protein level of PLN remains unchanged and this results in an increased ratio of 
PLN:SERCA2a with more inhibited SERCA2a fractions. Additionally, phosphorylated PLN 
levels are decreased, resulting in a reduced SERCA2a activity49. This reduced PLN 
phosphorylation might be an effect of receptor downregulation or desensitization of the ß-
adrenergic pathway50. Additional activation of phosphatases may also lead to higher PLN 
dephosphorylation and failing cardiac conditions40,51. The decrease in HAX-1, I-I or PKA 
phosphorylation contributes to reduced SERCA2a activity, whereas Hsp20 is significantly 
increased in failing hearts suggesting compensatory mechanisms. 
In summary, the function of the PLN/SERCA2a modulators underlie regulatory mechanisms 
under physiological and pathophysiological conditions. There is a huge effort to reverse the 
contractile failure by i.e. SERCA2a gene therapy52 to restore the PLN/SERCA ratio  and re-





1.7 Aim of the thesis 
Phospholamban is a central regulator for Ca2+ uptake into the SR and for cardiomyocyte 
contractility. During heart failure, Ca2+ handling is altered by reduced expression of SERCA2a 
while the PLN level is unchanged. Hence, the rate of relaxation and contractility is reduced. 
We hypothesize that PLN binds potentially to other important SER proteins and thereby 
regulates the reuptake of Ca2+ into the SR. 
This study was designed to explore novel interacting proteins of phospholamban by two 
different unbiased proteomic approaches. Here we used the bottom-up complexome profiling 
approach to identify protein-protein interactions in the native environment. The advances of 
the native membrane analysis by blue native gel electrophoresis were coupled with mass 
spectrometry analysis to identify migration profiles for multiple detected proteins. The overlap 
of migration profiles and the alignment by hierarchical clustering will allow the identification of 
novel cardiac protein complexes and assemblies, as well as the identification of previously 
unknown interactors. 
In parallel, an alternative PLN targeted APEX2 proximity labeling assay was used to identify 
potential interactions in living neonatal rat cardiomyocytes. This approach will allow the 
labeling of proteins in the proximity of PLN by the covalent transfer of biotin-phenol and the 
extraction of labeled proteins after cell lysis. Besides the known interactors of phospholamban, 
we expect the enrichment of previously unknown. 
Taken together, the identification of novel phospholamban interactors will elucidate new 
insights into the interactome and the regulatome of cardiac contractility. Furthermore, these 





2 Material and Methods 
2.1 Material 
2.1.1 Buffer conditions 
CBFHH buffer  
NaCl 37 mM 
KCL 5.4 mM 
KH2PO4 0.44 mM 
Na2HPO4 x 2 H2O 33.5 mM 
Glucose 5.6 mM 
HEPES 20 mM 
MgSo4 0.8 mM 
In 500 mL ddH2O, pH 7.4  
 
 
NRCM cultivation medium  
FBS 10% (v/v) 
5-Bromo-2’-deoxyuridine 10 mM 
Pen/Strep 1% (v/) 
In 500 mL DMEM-1 g/L D-glucose (Thermo Fisher) 
 
 
HEK293A cell culture medium  
FBS 10% (v/v) 
L-glutamine 2 mM 
Pen/Strep 1% (v/) 
In 500 mL DMEM-low glucose (Sigma-Aldrich) 
 
 
APEX2 biotinylation Quenching buffer  
Trolox 5 mM 
Sodium azide 10 mM 
Sodium ascorbate 10 mM 





APEX2 biotinylation RIPA Quenching buffer 
Trolox 5 mM 
Sodium azide 10 mM 
Sodium ascorbate 10 mM 
Tris HCl, pH 7.4 50 mM 
NaCl 150 mM 
Triton-X-100 1% (v/v) 
Sodium doxycholate 0.5% (w/v) 
Sodium dodecylsulfate 0.2% (v/v) 
In 10 mL ddH2O pH 7.4, tablet Complete mini EDTA protease inhibitor (Roche) 
  
 
Biotin pulldown Urea buffer  
Tris HCl, pH 8 50 mM 
Urea 2 mM 
In 100 mL ddH2O, pH 8  
 
 
Biotin elution buffer  
Biotin 2 mM 
Sodium dodecylsulfate 2% (v/v) 
In 1 mL ddH2O, pH 8  
 
 
iPSC culture medium  
Thiazovivin 2 µM 
In 500 mL StemMACS iPS-Brew stem cell culture media, Miltenyi Biotec 
 
 
Cardio differentiation medium  
Human recombinant albumin 0.5 mg/mL 
L-ascorbic acid 2-phosphate 0.2 mg/mL 
In 500 mL RPMI 1640 cell culture medium with Glutamax and HEPES (Thermo Fisher) 
 
 
Cardio culture medium  
B27 2% (v/v) 
L-ascorbic acid 2-phosphate 0.2 mg/mL 






Tris HCl, pH 7.4 50 mM 
NaCl 150 mM 
NP40 1% (v/v) 
Sodium doxycholate 0.5% (w/v) 
Sodium dodecylsulfate 0.2% (v/v) 
In 10 mL ddH2O pH 7.4, 1x tablet Complete mini EDTA protease inhibitor (Roche), 
1x tablet PhosSTOP protease inhibitor (Roche) 
 
 
5x SDS sample buffer 
Tris HCl, pH 7.4 191.6 mM 
Glycine 1.92 M 
Sodium dodecylsulfate 34.69 mM 
ß-mercapto ethanol 5% (v/v) 
In 50 mL ddH2O pH 8.3 
 
 
CHAPS co-immunoprecipitation buffer 
Tris HCl, pH 7.4 50 mM 
NaCl 150 mM 
CHAPS 1% (w/v) 
EDTA 1 mM 
1x tablet Complete mini (Roche) In 10 mL 
1x tablet PhosSTOP (Roche) In 10 mL 
In 50 mL ddH2O, pH 7.4  
 
 
Blue native homogenization buffer  
Sucrose 250 mM 
Tris HCl, pH 7.4 10 mM 
EDTA 1 mM 
1x tablet Complete mini (Roche) In 10 mL 
1x tablet PhosSTOP (Roche) In 10 mL 
In 50 mL pH 7.4 
 
 
Solubilization buffer A  
NaCl 50 mM 
Imidazole 50 mM 
EDTA 1 mM 
Aminocaproic acid 1 mM 






Blue native anode buffer  
Imidazole 25 mM 
In 1 L pH 7.0 
 
 
Blue native cathode buffer B  
Tricine 50 mM 
Imidazole 7.5 mM 
Coomassie Blue G-250 0.02% (w/v) 
In 1 L pH 7.0 (do not adjust) 
 
 
Blue native cathode buffer B/10  
Tricine 50 mM 
Imidazole 7.5 mM 
Coomassie Blue G-250 0.002% (w/v) 
In 1 L pH 7.0 (do not adjust) 
 
 
Coomassie Blue solution  
Coomassie Blue G-250 5% (w/v) 
Aminocaproic acid 500 mM 
In 1 mL  
 
 
Mouse heart perfusion buffer  
NaCl 120.4 mM 
KCl 14.7 mM 
KH2PO4 0.6 mM 
Na2HPO4 x 2 H2O 1.2 mM 
MgSO4 x 7 H2o 1.2 mM 
HEPES 10 mM 
NaHCO3 4.6 mM 
Taurin 30 mM 
2,3-Butanedione monoxime 10 mM 
Flucose 5.5 mM 
In 1 L ddH2O, pH 7.4  
 
 
Mouse heart digestion buffer 
Collagenase type II 2 mg/mL 
CaCl2 40 ~M 






Mouse heart STOP buffer 
Bovine calf serum 10% (v/v) 
CaCl2 12.5 µM 
In 50 mL perfusion buffer, pH 7.4  
 
 
Blocking buffer (immunofluorescence) 
Bovine calf serum 10% (v/v) 
Triton-X-100 0.2% (v/v) 





















a-actinin Mouse Monoclonal  Santacruz A7811 1:1000   
CAV3 Mouse Monoclonal  BD 
Bioscience 
610421   1:250 
CAV3 Rabbit Polyclonal  Abcam Ab2912 1:2000   
GAPDH Mouse Monoclonal  Biotrend 5G4Mab6C5 1:160000   
GFP Mouse Monoclonal  Proteintech HRP-66002 1:5000   
Myc Rabbit Polyclonal  Sigma-
Aldrich 
C3956  1:500  
PLN Mouse Monoclonal 2D12 Abcam Ab2865 1:2000 1:500 1:250 
SERCA2a Rabbit Polyclonal  Badrilla A010-20 1:2000 1:500 1:250 
SLMAP Mouse Monoclonal 2A7 Santa cruz Sc-100957  1:250  
SLMAP Rabbit Polyclonal  Sigma-
Aldrich 
HPA002357 1:1000 1:50 1:50 
V5 Mouse Monoclonal H00007871-
M08 
Invitrogen R960-25 1:1000 1:500  


















Donkey Polyclonal LI-COR P/N926-
32212 




Donkey Polyclonal LI-COR P/N926-
68072 




Donkey Polyclonal LI-COR P/N926-
32213 




Donkey Polyclonal LI-COR P/N926-
68073 




Goat Polyclonal Thermo 
Fisher 
A-21052  1:1000  
Goat anti-rabbit 
Alexa Fluor 514 




 1:1000  
Goat anti-rabbit 
STAR 635P  




Goat Polyclonal Abberior 2-0002-007-5  1:1000 1:300 
Goat anti-rabbit 
STAR 580  











DNA vector Source 
pcDNA3-V5-APEX Gift from Prof. Peter Rehling  
pdDNA3-YFP-PLN Gift from Prof. Viacheslav Nikolaev  
pcDNA3-V5-APEX2-PLN Cloning 
pcDNA3-V5-APEX2-PLN∆(1-29) Cloning 
pEF.myc.ER-E2-Crimson Gift from Benjamin Glick (Addgene plasmid 
#38770) 
 
2.1.4 Cell lines 
Cell lines  
Human embryonic kidney 293A cells CRL 1573, ATCC 
Neonatal rat cardiomyocytes Primary cell isolation 





4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid Sigma 
Acetic Acid Roth 
Acrylamide 2x SERVA 
Acrylamide/Bis-Acrylamide solution Roth 
Agarose Lonza 
aminocaproic acid Sigma 
Ammonium persulfate Sigma 
Ampicillin Roth 
ampicillin Roth 
Biotin (d-) SUPELCO 
Biotinphenol Iris Biotech 
Bis-Acrylamide 2x SERVA 
Bovine Serum Albumin  Gibco 
Bromdesoxyuridin Sigma 
Bromophenol blue Sigma 
calcium chloride Sigma 
CHAPS Roth 
Collagenase Type 2 Worthington 
Coomassie Blue G-250 SERVA 




Dulbeccos modified eagle medium Biochrome  
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EDTA 0.5 M solution AppliChem 
EGTA Sigma 
Ethanol Merck Millipore 
EZ Blue Gel staining Sigma 
Fetal Bovine Serium Invitrogen 
Fetal Calf Serum  Thermo Fisher 
Glucose Sigma 
Glycerol / glycerin Roth 
Glycin Roth 
HEPES Roth 
Hydrochloric acid fuming 37 % Roth 
Hydrogen peroxide Sigma 
Imidazole Sigma 
Isopropyl β-D-1-thiogalactopyranoside Sigma 
kanamycin Roth 
L-Glutathione reduced Sigma 
LB agar agar  Applichem 
LB Agar powder AppliChem 
LB Medium AppliChem 
Lysozym from chicken egg Sigma 
Magensium sulfate monohydrate Sigma  
Methanol Roth 
Milk, powdered blotting grade Sigma 
Nonidet P40 USB 
ortho-Phosphoric acid 89 % Merck Millipore 
Penicillin-Streptomycin Sigma 
Phenylmethylsulfonyl fluoride Sigma 
Phosphate bufferd saline Gibco, Life technologies 
PhosSTOP tablet Roche 
Pierce Bovine Serum Albumin Standard  Thermo Fisher 
Potassium chloride Sigma  
Potassium dihydrogenphosphate Sigma  
Protease Inhibotor tablet Roche 
rat tail collagen type 1 Corning 
Roti® Block Roth 
SILAC DMEM Flex Media  Thermo Fisher 
Sodium ascorbate Sigma 
Sodium azide Merck Millipore 
Sodium chloride Roth 
Sodium chloride Sigma  
Sodium deoxycholate Sigma 
Sodium dodecylsulfate Roth 
Sodium dodecylsulfate (20% solution) Roth 

















cDNA synthesis Quanta Biosciences 
Dynabeads protein G Thermo Fisher 
midi plasmid isolation Qiagen 
mini Plasmid isolation Qiagen 
Nucleo Spin Gel and PCR clean-up Macherey-Nagel 
Pierce™ BCA Protein Assay Kit Thermo Fisher 
Pierce™ Biotinylated Protein  
Interaction Pull-Down Kit 
Life technologies 
QIAShredder kit Qiagen 




Absorption/fluorescence plate reader Teacan 
Blotting Station AA Hoeffer 
Breeding cabinet (E.coli), Inforst HAT Ecotron 
Breeding cabinet (cell culture), HERAcell 150i Thermo Fisher 
Centrifuge Sorva 
Confocal microscope Zeiss 
DNA Camera Hero Doc plus Herolab 
Potter homogenizer RW20 digital IKA 
Electrophoresis Power Supply Bio-Rad 
Magnet-stirrer RCT standard IKA 
Confocal Microscope LSM880 Zeiss 




Rotating wheel PDR-35 Grant-bio 
Shaker table Duomax 1030 Heidolph 
STED microscope Leica 
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Table top centrifuge HERAEUS Pico 17 Thermo Fisher 
Table top centrifuge HEAREUS Fresco Thermo Fisher 
Thermocycler, labcycler SensoQuest 
Thermomixer Eppendorf 
Ultra turrax D1 Miccra 
Ultracentrifuge Beckman coulter 
Vortexer Scientific industries 
Waterbath Memmert 




Eppendorf Tubes 1.5 ml Eppendorf 
Eppendorf Tubes 2.0 ml Eppendorf 
Reaction tube 15 ml Sarstedt 
Reaction tube 50 ml Sarstedt 
PCR tube 200 µl Sarstedt 
Pipett tips 10 µl Sarstedt 
Pipett tips 200 µl Sarstedt 
Pipett tips 1000 µl Sarstedt 
Pipette 5 ml Sarstedt 
Pipette 10 ml Sarstedt 
Pipette 25 ml Sarstedt 
Pipette 50 ml Sarstedt 
Gel Loader Tips Sarstedt 
Pipett filter tips 10 µl Sarstedt 
Pipett filter tips 200 µl Sarstedt 
Pipett filter tips 1000 µl Sarstedt 
Cellculutre  flask T25 Sarstedt 
Cell culture flask T75 Sarstedt 
Cell culture flask T175 Sarstedt 
6-well plate Greiner 
12-well plate Greiner 
24-well plate Greiner 
96-well plate Greiner 
Immobilon-P PVDF Membrane 0.45 µm Merck Millipore 
Immobilon-FL PVDF Membrane 0.45 µm Merck Millipore 
Sterile filter Milipore 
Sterile filter for buffer Milipore 
Cannula, 27G Braun 
Cannula, 20G Braun 
Cell scraper Sarstedt 
Low profile 96 well plate Bio-Rad 
syringe 1 ml Braun 
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ultracentrifuge tube I Beckman 




Word Microsoft Inc. 
Powerpoint Microsoft Inc. 
Excel Microsoft Inc. 
Outlook Microsoft Inc. 
FijiImage https://imagej.net/Fiji 
Prism (Version 7.03) Graphpad 
Cluster3.0 Open source clustering software 
Mendeley www.mendeley.com 







2.2.1 Mouse husbandry 
The phospholamban germline knockout (PLN KO) mouse (C57Bl/6N) was backcrossed for ten 
generations in the B6N background. Mice were housed at the Max Planck Institute (MPI) for 
experimental medicine Göttingen and the central animal facility (ZTE) of the University Medical 
Center Göttingen. The cages were part of a ventilated system (IVC racks), equipped with 
woodchips and nesting material. The rooms were kept at 20 °C to 24 °C and 45% to 65%, with 
a light/dark cycle of 12 h dark and 12 h light. Mice had access to water and food ad libitum. 
Mice for breeding were genotyped using ear punch tissue from P21. For organizing the 
breeding at the MPI, the PYRAT software was used. All animal procedures were reviewed by 
the Institutional Animal Care and Use Committee by the University Medical Center Göttingen 
and approved by veterinarian state authority (LAVES, Oldenburg, Germany) in compliance 
with the humane care and use of laboratory animals (33.9-42502-04-16/2102). Unless 
indicated otherwise, male mice aged 12-16 weeks were used for experimental procedures. 
2.2.2 Mouse Genotyping 
For mouse genotyping, the ear punch tissue was lysed according to the manufacturer’s 
protocol (DirectPCR Lysis Reagent Ear, Peqlab). 1 µl of crude lysate was used for polymerase 
chain reaction (PCR) in a Thermocycler (Sensoquest) according to protocols below (Table 
2,Table 3). The obtained PCR products were supplemented with 10x loading dye and 
separated on a 2% agarose gel by gel electrophoresis for 40 min at 110 V in 1x TAE buffer. 
The expected PCR product sizes are given in Table 4. 
Table 2 Genotyping protocol PCR mix 
 PLN KO 
Manoo Taq 5x buffer 5 µl 
MgCl2 (50 mM) 1.5 µl 
dNTP’s (10 mM each) 0.5 µl 
Primer Fwd (PLN1F) (10 µM) 0.75 
Primer Fwd II (NEO3) (10 µM) 0.75 
Primer Rev (IMU8) (10 µM) 1 µl 
DNA 1 µl 
H2O 14.3 µl 
Mango Taq (5 U/µl) 0.2 µl 




Table 3 PCR protocol for PLN KO mouse genotyping 
 Temperature Time 
Preincubation 95 °C 2 min 
Denaturation 95 °C 1 min 
Annealing 58 °C 30 sec 
Elongation 72 °C 1 min 
Number of cycles 35x  
Final elongation 72 °C 7 min 
End 4 °C hold 
 
Table 4 PLN KO mouse genotyping primer 
Gene Primer sequence Expected sizes 
Pln wt fwd I 5’-CCAGTCTGGGGAATAAATGG-3’ WT: 900 bp 
Pln Neo fwd II 5’-TCCTCGTGCTTTACGGTATC-3’ Het: 400 and 900 bp 
Pln rev 5’-TGTGGGTTTGCAAAGTTAGGC-3’ KO: 400 bp 
 
 
2.2.3 Cloning of V5-APEX2-PLN and V5-APEX2-PLN(1-29) 
The V5 epitope tagged APEX2 pcDNA3 construct was a gift from Prof. Peter Rehling (Institute 
for Biochemistry, Göttingen). The wildtype canine phospholamban (PLN) cDNA sequence was 
a gift from Prof. Viacheslav Nikolaev (UKE, Hamburg). The PLN cDNA was amplified according 




The pcDNA3-V5-APEX2 vector was linearized using XhoI (NEB) restriction enzyme digestion. 
The PLN PCR product and the linearized vector were cleaned up using the Nucleo Spin Gel 
and PCR clean-up (Macherey-Nagel) following the manufacturer’s protocols. The PLN PCR 
fragment was cloned into the linearized V5-APEX2 vector by ligation (In-Fusion HD Cloning 
Kit, Clonetech). The vector was transformed into Stellar competent cells (Clonetech) and 
plated on LB-agar plates with 100 µg/ml ampicillin for overnight at 37 °C. Ampicillin resistant 
clones were picked and amplified in 5 mL LB medium containing ampicillin overnight at 37 °C. 
Plasmids were isolated using the QIAprep Miniprep kit (Qiagen) according to the 
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manufacturer’s protocol. Plasmids were sequenced by Microsynth Seqlab GmbH (Göttingen) 
using standard primers. 
CMV-fwd: 5’-CGCAAATGGGCGGTAGGCGTG-3’ 
BGH-rev: 5’-TAGAAGGCACAGTCGAGG-3’ 
The DNA plasmid carrying the deletion of the cytosolic domain of PLN (pcDNA3-V5-APEX2-
PLN(1-29)) was amplified by InFusion-PCR according to manufacturer’s protocol (In-Fusion 
HD Cloning Kit, Clonetech) using the following primer pair: 
Fwd-5’-AACCTATTTATCAATTTCTGTCTCATC-3’ 
Rev-5’-ATTGATAAATAGGTTGCTCGAGCCGCTGCCCCC-3’ 
The resulting construct was ligated, amplified and sequenced as described. 
 
2.2.4 Adenoviral constructs for transduction 
Adenoviral vectors and particles were custom made by Sirion Biotech (Martinsried, Germany). 
For the generation of adenviral vectors, pcDNA3-V5-APEX2-PLN and pcDNA3-V5-APEX2-
PLN(1-29) were cloned into the adenoviral shuttle plasmid pO6A5-CMV. By recombination, 
these constructs were transferred into the adenoviral expression vector SIR-BAC-Ad5. After 
restriction enzyme digestion with PacI, vector DNA was transfected into HEK293 cells for 
adenoviral particle production. The expression constructs were designed for constitutive 
expression under the CMV promoter with eGFP as expression control separated by an internal 
ribosomal entry side (IRES) sequence (Figure 5). Purified adenoviral particles serotype V Ad5-
APEX2-PLN-IRES-eGFP and Ad5-APEX2-PLNΔ(1-29)-IRES-eGFP were used for the 
transduction of neonatal rat cardiomyocytes (NRCMs).  
 
 
Figure 5 Adenoviral vector constructs for transduction of NRCMs 
For APEX2 proximity labeling in NRCMs, adenoviral vectors carrying APEX2-PLN and APEX2-PLNΔ(1-
29) were generated by Sirion Biotech (Martinsried, Germany). The expression constructs were designed 
for constitutive expression under the CMV promoter with eGFP as expression control separated by an 
internal ribosomal entry side (IRES) sequence. Adenoviral particles subclass V (Ad5) were used for 
transduction to target APEX2 constructs into NRCMs. 
 
APEX2-PLN CMV V5-APEX2-PLN IRES eGFP




2.2.5 SDS gel electrophoresis 
Samples for detection in immunoblotting were lysed and homogenized in RIPA buffer 
containing protease and phosphatase inhibitors (Roche). Depending on the sample, 
mechanical disruption was performed by three times 10 sec with the Miccra D-1 ultra turrax 
(heart tissue), 50 strokes using a potter homogenizer at 2000 rpm (isolated cardiomyocytes) 
or 10 strokes with a 27-gauge needle (cultivated HEK or NRCMs). The homogenates were 
solubilized for 1 h at 4 °C with rotation, followed by centrifugation at 13000 x g at 4 °C. After 
collecting the supernatant, protein concentrations were determined using Pierce BCA protein 
Assay Kit (Thermo Fisher). For immunoblotting, 10 µg of protein was supplemented with 5x 
SDS sample buffer and subjected on 4-20% gradient Tris-Glycine-SDS gel (Thermo Fisher) or 
10% Tris-SDS acrylamide gels. The samples were resolved at constant 200 V for 
approximately 50 min or at 80 V for 30 min and 120 V for 90 min, respectively. A Tris-Glycine 
buffer was used as anode and cathode buffer. For molecular weight estimation, a pre-stained 
protein marker was used (Thermo Fisher). 
 
2.2.6 Immunoblotting 
For immunoblotting, blue native or SDS gel was equilibrated in transfer buffer and proteins 
were transferred onto polyvinylidene fluoride (PVDF) membranes (0.45 mm, Immobilon-FL, 
Merck Millipore). In short, PDVF membranes were activated in methanol and equilibrated in 
transfer buffer. The protein transfer was performed using an electrophoretic transfer cell at 
constant 100 V for 1 h for SDS gels and 2 h for BN gels at 4 °C. After blotting, PVDF 
membranes were blocked in 5% non-at milk (w/v) in TBS-T for 1 h at room temperature. 
Primary antibodies were diluted in 5% milk in TBS-T and membranes were incubated overnight 
at 4 °C. After washing the PVDF membranes 3x for 10 min with TBS-T, they were incubated 
with anti-mouse or anti-rabbit fluorescent secondary antibodies, diluted 1:10000 in 1x Rotiblock 
in TBS-T (Roth), for a minimum period of 1 h at room temperature with agitation. Fluorescence 
signals were captured with the Odyssey CLX imaging system (LI-COR). For analysis of 
biotinylated proteins, PVDF membranes were incubated with fluorescent-labeled streptavidin 
(RD680, LI-COR) for 1 h at RT in the dark. Signal intensities were analyzed by Image Studio 
Lite Version 5.2 (LI-COR) for quantification in Microsoft Excel. 
 
2.2.7 Co-Immunoprecipitation of phospholamban interacting proteins 
Ventricular tissue from PLN WT and KO mice was collected after perfusion with isotonic NaCl 
solution for 2 min using the Langendorff perfusion system. After that, samples were snap 
frozen in liq. N2, and stored at -80 °C until further analysis. For co-immunoprecipitation, 
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ventricular tissue was thawed on ice and homogenized in non-denaturing Co-IP lysis buffer 
using the D-1 ultra turrax (Miccra). Homogenates were solubilized for 1 h at 4 °C with rotation, 
followed by a centrifugation step at 5000 x g for 20 min at 4 °C. Supernatant of lysates were 
collected and protein concentration was determined using the Pierce BCA-protein assay 
(Thermo Fisher). For the antibody-lysate binding, lysates containing 500 µg of protein were 
incubated with 4 µl of anti-PLN primary antibody (ab2865, abcam) in a total volume of 1 mL 
Co-IP lysis buffer for overnight at 4 °C with rotation. For immunoprecipitation, 30 µl of 50% 
slurry magnetic beads (Dynabeads Protein G, Thermo Fisher) were washed with 500 µl Co-IP 
lysis buffer and incubated with the antibody-lysate mix for 1.5 h at 4 °C with rotation. After that, 
samples were placed on a magnet (DynaMag2 magnet, Thermo Fisher) and beads-antibody-
antigen complex was washed three times with ice-cold 1 mL Co-IP lysis buffer for 10 min each 
at 4 °C with rotation. To avoid co-elution of proteins bound to the tube wall, the beads-antibody-
antigen complex was resuspended in 200 µl Co-IP lysis buffer and transferred into a new tube. 
For elution of the antibody-antigen complex, 50 µl of 2x SDS sample buffer were added. After 
vigorous mixing for 10 min at RT, the supernatant was collected, and samples were analyzed 
by SDS-PAGE and immunoblotting. 
 
2.2.8 Cell cultivation of HEK293A 
HEK293A cells (ATCC) were cultivated in T75 flasks (Greiner) in Dulbecco’s Modified Eagle’s 
Medium (DMEM low glucose, Sigma) supplemented with 10% (v/v) fetal bovine serum (FBS, 
Thermo Fisher) 2 mM L-glutamine GlutaMAX (Sigma-Aldrich) and penicillin/streptomycin 
(Sigma-Aldrich). Cells were cultivated under humidified conditions with 5% CO2 at 37 °C 
(Heracell VIOS 250i, Thermo Fisher) and passaged every 3-4 days using trypsin/EDTA 
(Sigma) digestion. 
 
2.2.9 Isolation of neonatal rat cardiomyocytes 
For the isolation and purification of neonatal rat cardiomyocytes (NRCMs) hearts from 0 to 3 
days old wistar rats were collected and washed in cooled CBFHH buffer. After removing the 
atria, ventricles were washed in CBFHH buffer and cut in half.  By using a combination of 
enzymatic and mechanical dissociation cardiomyocytes were dissociated from the ventricles 
(Neonatal Heart Dissociation Kit, Miltenyi Biotec) according to the manufacturer’s protocol. In 
short, minced ventricular tissue was applied to a stainless-steel filter mesh (pore size 250 µm, 
Thermo Fisher) to remove larger particles. Cells in the resulting suspension were pelleted by 
centrifugation at 60 x g for 20 min at 4 °C (HERAEUS Multifuge X1R, Thermo Fisher) and 
resuspended in 1x PBS supplemented with Pen/Strep. For the specific enrichment of 
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cardiomyocytes, a two-layer Percoll (GE Healthcare) density gradient with 63% and 40.5% 
was overlayered with the cell suspension and centrifuged at 3000 x g for 30 min at room 
temperature without deceleration (HERAEUS Multifuge X1R, Thermo Fisher). Cardiomyocytes 
were separated from fibroblasts based on their different density and harvested from the Percoll 
interface between 63% and 40.5% using a 10 mL glass pipette. The enriched cardiomyocytes 
were suspended in prewarmed NRCM cultivation medium without FBS (Thermo Fisher) and 
immediately pelleted at 1200 x g for 5 min at room temperature. Finally, cardiomyocytes were 
suspended in warm NRCM cultivation medium supplemented with heat inactivated 10% 
(vol/vol) FBS.  
To determine the cell concentration, 50 µl of cell suspension was mixed with 50 µl trypan blue 
solution (Sigma-Aldrich) and cardiomyocytes were counted using a Neubauer improved 
chamber (LO-Labor Optik). NRCMs were seeded on collagen coated 6-well culture plates 
(5x105 cells/well) or glass cover slides (12-well culture plates, 2.5x105 cells/well) for the APEX 
proximity labeling or immune fluorescence staining, respectively, and cultivated under 
humidified conditions with 5% CO2 at 37 °C. The NRCM cell culture medium was replaced 
every second day. 
 
2.2.10 NRCM cultivation in SILAC medium   
For ratiometric stable isotope labeling with amino acids in cell culture (SILAC), SILAC DMEM 
Flex Media lacking lysine and arginine (Thermo Fisher) was supplemented with 10% heat 
inactivated FBS, 100 µM BRDU, 0.11 g/L sodium pyruvate, 1 g/L glucose, 100 U/mL 
penicillin/streptomycin mix and the respective radiolabeled amino acids L-arginine and L-
lysine. Heavy SILAC media contained L-arginine [13C6,15N4]HCl (Arg-10) and L-lysine 
[13C6,15N2]HCl (Lys-8) (Eurisotop); medium SILAC media contained L-arginine [13C6]HCL (Arg-
6) and L-lysine-4,4,5,5-d4 (Lys-4) (Eurisotop); light SILAC media contained light L-arginine 
(Arg-0) and L-lysine (Lys-0) using DMEM-media (Biochrome). After isolation and purification 
of NRCMs (as described above), the cells were suspended in the respective SILAC cultivation 
media without FBS and immediately pelleted at 1200 x g for 5 min at room temperature. The 
pelleted NRCMs were suspended in SILAC cultivation media supplemented with FBS, and 
5x105 cells were seeded for APEX2 proximity labeling on collagen coated 6-well culture plates. 
NRCMs were cultivated under humidified conditions with 5% CO2 at 37 °C for 13 days in 2 mL 





2.2.11 Human induced pluripotent stem cell differentiation 
Differentiation and cultivation of human induced pluripotent stem cells (iPSC) was performed 
by Dr. Lukas Cyganek and the Stem Cell Unit (University Medical Center, Göttingen). Directed 
differentiation of human iPS cells into a ventricular phenotype was performed via WNT 
signaling modulation, as described previously53. The differentiation of iPS cells was initiated at 
80-90% confluence on Matrigel coated 6-well-plates with cardio differentiation medium and 
sequential treatment with 4 µM CHIR99021(Merck Millipore) for 48 h, followed by 5 µM IWP2 
(Merck Millipore) for additional 48 h. Medium was changed to cardio culture medium at day 8. 
To prevent detachment and enhance selection, differentiated cultures were digested with 
collagenase B (Worthington Biochemical) and 0.25% Trypsin/EDTA at day 12-15 (Thermo 
Fisher) and replated in lower cell density on Matrigel coated plates. Cardiomyocyte selection 
was performed using cardio selection medium for 5 days and a medium change every second 
day. For further maturation and cultivation, iPSC derived cardiomyocytes were cultured in 
cardio culture medium with medium change every 2-3 days. For protein analysis, cultured iPSC 
derived cardiomyocytes were washed with 1x PBS, harvested with a cell scraper (Sarstedt), 
pelleted at 13000 x g for 10 min at 4 °C, and frozen in liquid N2 and stored at -80 °C for further 
analysis. For immunofluorescence and immunoblot analysis the human iPSC lines isWT1.14 
(UMGi014-C.14) were used. 
 
2.2.12 Transfection of HEK293A cells and NRCM 
For transfection of HEK293A cells and NRCM, cells were seeded in 6-well culture plates at a 
density of 2x105 cells per well 24 h prior to plasmid transfection. After reaching a confluency 
of approximately 70%, the cells were plasmid transfected with Lipofectamine 3000 (Thermo 
Fisher). Therefore, 2 µg of plasmid DNA and P3000 (2 µl/µg DNA) were added to DMEM 
medium without supplements. In parallel, Lipofectamine 3000 (1 µl/µg DNA) was added to 
DMEM medium without supplements and vortexed for 2-3 sec. Both DNA/P3000 and 
Lipofectamine 3000 containing DMEM were mixed in a ratio of 1:1 and incubated for 10 min at 
room temperature. Cells were washed once with 1x PBS, before the DNA-Lipofectamine 
complex was added.  After 24 h of incubation, the cells were harvested for further experiments. 
In preparation for immunofluorescence staining, cells were seeded in 12-well culture plates on 
glass cover slides (Ø 18 mm) with a density of 1x105 cells per well and, after 24 h, transfected 




2.2.13 Adenoviral transduction of NRCMs 
For NRCM transduction, adenoviral particles were diluted in 1 mL cultivation medium without 
FBS with the respective multiplicity of infection (MOI) and applied to the cells. After 2 h, 1 mL 
of cultivation medium with FBS was added and NRCMs were cultured for 48 h under humidified 
conditions with 5% CO2 at 37 °C. The adenoviral transduction was monitored by eGFP 
expression using a fluorescence microscope (Axio Vert.A1, Zeiss).  
For testing of the required multiplicity of infection, NRCMs were cultivated for 6 days before 
transduction. For ratiometric APEX2 proximity labeling, NRCMs were cultivated for 13 days in 
heavy, medium and light SILAC-medium before adenoviral transduction using a MOI of 10 and 
allowing for 48 h of expression.  
 
2.2.14 APEX2 Proximity Labeling 
APEX2 proximity labeling in HEK293A and NRCMs was conducted according to the published 
protocol by Hung et al.54. Therefore, HEK293A cells were transfected with 2 µg and NRCMs 
with 4 µg of plasmid for 24 h or NRCMs were transduced with adenoviral particles at a MOI of 
10 for 48 h as described above. Prior to biotinylation, cells were incubated in 1 mL cultivation 
medium supplemented with 500 µM biotin-phenol for 30 min at 37 °C. To initiate the 
biotinylation, a final concentration of 1 mM H2O2 was added with agitation for 1 min at room 
temperature. The reaction was stopped by washing the cells immediately with 2 mL quenching 
buffer thrice before a final washing step with ice cold 1x PBS. The cells were harvested on ice 
in 250 µl RIPA quenching buffer using a cell scraper, frozen in liquid N2 and stored at -80 °C 
until proceeding with cell lysis and enrichment of biotinylated proteins. 
 
2.2.15 Quantitative RT-PCR 
For quantitative real-time PCR, NRCMs were transduced with adenoviral particles APEX2-
PLN or APEX2-PLNΔ(1-29) for 48 h as described above. Subsequently, cells were harvested 
in 1x PBS using a cell scraper, pelleted and lysed using the QIAShredder homogenizer 
(Qiagen), and total RNA was isolated by using the RNeasy Mini Kit (Qiagen) according the 
manufactures protocol. RNA was reverse transcribed by qScript cDNA Super Mix (Quanta 
Biosciences) following the incubation protocol in Table 5. Quantitative real-time (qRT)-PCR 
was conducted in triplicate in 96-well plates (Bio-Rad) using the PerfeCTa SYBR Green 
Supermix (Quanta Biosciences) and the CFX96 (Bio-Rad) with the reported cycles ( 
Table 6). For relative quantifications, a mix of all samples was diluted 1:10 in multiple steps. 
Relative mRNA transcript levels (normalized to GAPDH) were calculated using the Bio-Rad 
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CFX Manager software version 3.1 and the CT (cycle number) method and are reported as 
fold change. The primers used are listed in Table 7. 
 
Table 5 First strand cDNA synthesis 
 Temperature Time 
Pre-incubation 25 °C 5 min 
cDNA synthesis 42 °C 30 min 
Inactivation 85 °C 5 min 
End 4 °C hold 
 
Table 6 qRT-PCR cycles 
 Temperature Time 
Preincubation 95 °C 60 sec 
Denaturation 95 °C 10 sec 
Annealing 60 °C 30 sec 
Number of cycles 39x  
Melt curve 65 °C – 95 °C 0.5 °C / 5 sec 
End 4 °C hold 
 
Table 7 qRT-PCR primer 
Gene Primer sequence 
EGFP fwd 5’-AGAACGGCATCAAGGTGAAC-3’ 
EGFP rev 5’-TGCTCAGGTAGTGGTTGTCG-3’ 
GAPDH Rat fwd 5’-AAGGTCATCCCAGAGCTGAA-3’ 
GAPDH Rat rev 5’-AGGAATGGGAGTTGCTGTTG-3’ 
 
2.2.16 Cell lysis, enrichment and elution of biotinylated proteins 
For cell lysis, samples were thawed on ice disrupted with 15 strokes through a 27 gauge needle 
and cleared by centrifugation at 13000 x g for 10 min at 4 °C. Protein concentration of the 
supernatant was determined using the Pierce 660 nm Protein Assay Kit (Thermo Fisher 
Scientific). For the ratiometric APEX2 proximity labeling approach, lysates of heavy, medium 
and light labeled NRCMs were mixed in a ratio of 1:1:1 for a total of 250 µg of protein. 
Biotinylated proteins were enriched by an avidin pulldown assay (Thermo Scientific). For that, 
80 µl of slurry monomeric avidin beads (Thermo Fisher Scientific) were loaded into a spin 
column and equilibrated twice in 500 µl RIPA quenching buffer. The supernatant was removed 
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by centrifugation at 100 x g for 30 sec at 4 °C. 250 µg of cleared lysate was added to the 
monomeric avidin and incubated for 1 h at 4 °C with rotation. Avidin beads with bound 
biotinylated proteins were washed twice with 500 µl RIPA quenching buffer, once with 2 M 
urea washing buffer followed by two washing steps with RIPA quenching buffer. Further, 
columns were dried for 2 min by centrifugation at 2000 x g. Finally, biotinylated proteins were 
eluted in 75 µl elution buffer for 15 min at room temperature and 15 min at 70 °C. The elution 
fraction was collected by centrifugation at 100 x g for 1 min at 4 °C and supplemented with 
25 µl of 4x SDS sample buffer. For ratiometric APEX2 proximity labelling in NRCMs, eluted 
proteins were analyzed by mass spectrometry (LC-MS/MS). 
 
2.2.17 Transverse aortic constriction (TAC) to generate pressure overload in 
mice 
To induce aortic pressure overload, the transverse aorta was constricted by a minimally 
invasive surgery as described previously55. In surgery, mice were anesthetized with 1.5% 
isoflurane in O2. A horizontal incision at the jugulum was made to display the transverse aorta. 
For the constriction, a 27 gauge needle was tied against the aorta and bended with a 5-0 non-
absorbable suture. The 27 gauge needle was removed and the skin closed with a 6-0 suture. 
After surgery, the mice were placed on a heating plate (37 °C) and monitored to full recovery 
from isoflurane anesthesia. Sham operated mice underwent the same procedure, only without 
constriction of the transverse aorta. After surgery, buprenorphine (0.1 mg/kg) and carprofen (5 
mg/kg) pain medication was given subcutaneously the following days. During the postoperative 
recovery, the health status and the body weight was monitored daily. 1 or 4 weeks after TAC 
operation, hearts were collected for ventricular cardiomyocyte isolation or ventricular tissue 
sampling. 
 
2.2.18 Isolation of adult mouse ventricular cardiomyocytes 
Isolation of adult mouse ventricular cardiomyocytes was performed according to Wagner et 
al.56. Briefly, adult mice (between 12 and 14 weeks) were anesthetized with 3% isoflurane in 
O2 and sacrificed by cervical dislocation. Hearts were rapidly extracted, and the proximal aorta 
was connected to a 21 gauge cannula. Using a modified Langendorff perfusion setup57, hearts 
were perfused with nominally Ca2+ free perfusion buffer for 4 min at 37 °C  and a flow rate of 
4 mL/min. Next, perfusion buffer was exchanged to collagenase type II containing perfusion 
buffer (600 U/mL, Worthington Biochemical Corporation) for 9 min at 37 °C. The ventricles 
were separated from the atria, gently minced in 2 mL collagenase containing perfusion buffer 
and triturated by 5 mL pipette to suspend the cells in solution. Digestion was stopped in 3 mL 
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stopping buffer. Isolated ventricular cardiomyocytes (VCM) were carefully washed three times 
with stopping buffer at room temperature and resuspended before plating on laminin coated 
cover slides for immunofluorescence staining. For WB analysis and membrane preparations, 
cells were washed once in 1x PBS and pelleted by gravity for 8 min at RT directly after isolation. 
Cell pellets were snap-frozen in liq. N2 and stored at -80°C until further experiments. 
 
2.2.19 Sample preparation of mouse heart tissue for biochemistry 
For sampling of ventricular tissue, heart extraction and connection to the Langendorff perfusion 
setup was conducted as described above. Hearts were perfused with isotonic NaCl buffer with 
a flow rate of 4 mL/min for 2 min at 37 °C. Atria were separated from ventricles, which were 
again separated in left and right ventricle under a binocular microscope. Tissues were snap-
frozen in liq. N2 and stored at -80 °C until further experiments. 
 
2.2.20 Sample preparation for confocal and STED immunofluorescence 
imaging 
For immunofluorescence imaging, isolated ventricular cardiomyocytes were plated on glass 
cover slides (Ø 18 mm, width 1.5 mm, Menzel) coated with 2 µl laminin (2 mg/mL) in perfusion 
buffer. After 30 min of sedimentation, cells were attached to the glass surface. The perfusion 
buffer was aspirated, and cells were immediately fixed with 4% paraformaldehyde (PFA, 
Sigma) in PBS for 5 min at room temperature. 
HEK293A cells or NRCM were seeded with a density of 1x105 cells on collagen or 2.5x105 
cells on laminin (2 mg/mL) coated cover slides ( 18 mm, width 1.5 mm, Menzel), respectively. 
Cells were cultivated in the respective cell culture medium under humidified conditions with 
5% CO2 at 37 °C (Heracell VIOS 250i, Thermo Fisher). After cultivation, cells were washed 
once with 1x PBS and fixed with 4% PFA for 5 min at room temperature. 
For immunostaining of iPSC derived cardiomyocytes (iPSC-CM), cultivated cells were 
detached using 0.25% trypsin/EDTA (Thermo Fisher), counted and reseeded on Matrigel 
coated cover slides ( 18 mm, width 1.5 mm, Menzel) in cardio recovery medium and 
cultivated for at least 7 days in cardio culture medium under humidified conditions with 5% CO2 
at 37 °C (Heracell VIOS 250i, Thermo Fisher). For fixation, cells were washed with 1x PBS 
and fixed in 4% Roti-Histofix (Carl Roth) for 20 min at room temperature. 
After fixation, cells were permeabilized and blocked in IF blocking buffer for at least 2 h at room 
temperature. Primary antibodies were diluted in 500 µl blocking buffer and applied to the cells 
for overnight incubation at 4 °C. The following day, cells were washed twice in blocking buffer. 
Anti-mouse or anti-rabbit secondary antibodies were diluted 1:1000 in 500 µl IF blocking buffer 
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and applied overnight at 4 °C in the dark. For confocal immunofluorescence microscopy, Alexa 
Fluor 633 and Alexa Fluor 514 conjugated secondary antibodies were used. For STED 
immunofluorescence microscopy, STAR 635P and STAR580 conjugated secondary 
antibodies were used. Excess secondary antibodies were washed away twice with 1x PBS for 
5 min and again for 10 min. The cover slides with the immunostained cells were embedded in 
mounting medium (ProLong Gold Antifade Mountant, Thermo Fisher) upside down on a glass 
objective and dried for overnight at room temperature in the dark. The next day, the edges of 
the cover slides were sealed with clear nail polish.  
 
2.2.21 Histology of ventricular heart tissue 
For immunofluorescence staining, ventricular tissue from PLN WT and KO mice were perfused 
for 2 min with isotonic NaCl buffer and subsequently fixed in 4% PFA overnight. The fixed 
tissue was embedded in paraffin, microtome sliced into 4 µm thick histological sections and 
plated on glass objectives. Prior to immunofluorescence staining, the heart sections were 
deparaffinized and rehydrated gradually (Table 8). Antigens were unmasked using a 10 mM 
sodium-citrate buffer for 40 min at 99 °C. For further incubation steps, the heart sections were 
encircled with an oil pen to allow the application of small volumes. For blocking and 
permeabilization, samples were incubated with 400 µl 4% BSA in PBS and 0.1% Triton-X100 
for 1 h at room temperature. Primary antibodies were diluted in 400 µl 4% BSA in PBS and 
applied overnight at room temperature. The next day, samples were washed three times for 
5 min in 1x PBS and incubated in anti-mouse or anti-rabbit secondary antibodies diluted 1:300 
in 400 µl 4% BSA in PBS for 2 h at room temperature. For STED immunofluorescence 
microscopy, STAR 635P and STAR580 conjugated secondary antibodies were used. 
Secondary antibodies were removed by washing three times for 5 min in 1x PBS. Heart 
sections were embedded in mounting medium (ProLong Gold Antifade Mountant, Thermo 
Fisher) on a glass cover slide and dried for overnight at room temperature in the dark. The 




Table 8 Deparaffinization and rehydration of paraffin embedded histological sections 
Reagent Time 
Xylol 2x 7 min 
EtOH 100% 2x 5 min 
EtOH 90% 2x 5 min 
EtOH 70% 5 min 
EtOH 50% 5 min 
EtOH 30% 5 min 
dH2O 5 min 
 
2.2.22 Confocal microscopy 
Confocal images were acquired with a Zeiss LSM 710 and LSM 880 using a Plan-Apochromat 
63x/1.40 ail objective and a pixel size of 50x50 nm. Alexa Fluor 514 and Alexa Fluor 633 
excitation was set to 514 nm and 633 nm and fluorophore emission was detected between 
520-620 nm and 640-740 nm, respectively. Confocal laser power was adjusted to maximize 
resolution following established protocols56. Raw images were processed with Fiji software 
(https://imagej.net/Fiji) using background subtraction (rolling ball radius: 50), local contrast 
enhancement, and smoothing (Gaussian, sigma 1 pixel). 
 
2.2.23 Immunofluorescence STED nanoscopy  
STED images were acquired with a Leica TCS SP8 system with a HC PL APO C2S 100x/1.40 
oil objective and a pixel size of 16.23 x 16.23 nm. STAR 635P and STAR 580 fluorophore 
excitation was set to 635 nm and 580 nm and fluorophore emission was detected between 
650-700 nm and 600-630 nm, respectively. For STED depletion of STAR 580 and STAR 635P, 
a 775 nm laser beam was used. Raw images were processed in Fiji (https://imagej.net/Fiji) 
using background subtraction (rolling ball radius: 50), local contrast enhancement, and 
smoothing (Gaussian, sigma 1 pixel). 
 
2.2.24 Membrane enrichment from isolated ventricular cardiomyocytes 
Frozen isolated ventricular cardiomyocytes were thawed on ice and resuspended in detergent-
free homogenization buffer (0.1 g cells / 1 mL homogenization buffer). The cardiomyocytes 
were disrupted with a 2 mL potter homogenizer (RW20 digital, IKA) for 100 strokes at 2000 rpm 
on ice. The homogenate was centrifuged at 400 x g for 10 min at 4 °C (HARAEUS Fresco21 
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centrifuge, Thermo Fisher). The resulting pellet was potter homogenized again in 1 mL 
homogenization buffer with 50 strokes and repeatedly centrifuged. The cleared lysates were 
combined and centrifuged at 3000 x g for 10 min at 4 °C to remove nuclei and cell debris. The 
perinuclear fraction (PNF) was differential centrifuged at 9000 x g, at 15000 x g for 20 min at 
4 °C, or ultracentrifuged at 100000 x g for 1 h at 4 °C (MLS50 swingout rotor; Optima MAX-XP 
Ultracentrifuge, Beckman Coulter). The resulting pellets were resuspended in homogenization 
buffer and the protein concentration was determined by Pierce BCA-Protein Assay (Thermo 
Fisher). For immunoblotting, the collected supernatants and resuspended pellets were 
prepared with a final 1x NuPAGE LDS sample buffer (4x, Thermo Fisher). For blue native gel 
electrophoresis, 50 µg or 100 µg of resuspended membranes were aliquoted and pelleted at 
15000 x g for 20 min or 100000 x g for 1 h at 4 °C (MLA-150 fixed rotor, Beckman Coulter). 
 
2.2.25 Membrane solubilization for blue native gel electrophoresis 
Enriched membrane fractions were solubilized in solubilization buffer A and solubilized with 
6 g per gram protein for 30 min on ice. Un-solubilized membranes were pelleted with 21000 x g 
for 20 min at 4 °C. The supernatant was supplemented with 1:10 (v/v) 50% glycerol and 1:10 
(v/v) coomassie blue solution. 50 µg or 100 µg of membranes were loaded on blue native gels 
for gel electrophoresis. 
 
2.2.26 Blue native gel electrophoresis 
Blue native gel electrophoresis (BN-PAGE) was conducted as published by Wittig, Braun and 
Schägger58. Enriched membranes were solubilized as described above. For BN-PAGE the 
PROTEAN II xi (Biorad) was used. For the separation of cardiac membranes, a tricine-imidazol 
gel with a 4-13% continuous gradient was cast with a gradient mixer (16x20 cm) and stored 
overnight at 4 °C to allow polymerization. The next day, a stacking gel was cast, chamber and 
gel was assembled, and filled with 1000 mL anode buffer and 300 mL cathode buffer B. 
Solubilized membranes were applied together with a native molecular weight marker (SERVA) 
and separated at 100 V for 20 min followed by 400 V. When the blue running front reached 
one third of the gel the cathode buffer was change to B/10. The BN gel was further separated 
at 400 V until the blue front reached the end. After the run, the BN gel was equilibrated in 
dH2O. For complexome profiling single gel lanes were cut in 60 equal slices, each slice further 
into smaller pieces and transferred into 0.5 mL reaction tubes with 200 µl dH2O. The gel pieces 
were subjected to tryptic digestion and mass spectrometry analysis as described below. 
For immunoblotting, the BN gel was equilibrated in transfer buffer and proteins were 
transferred onto a PVDF membrane at 100 V for 2 h at 4 °C. After blotting the PVDF membrane 
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was destained with pure methanol and subjected to blocking in 5% milk in TBS-T. The primary 
and secondary antibody incubations were conducted as described under ‘Complexome 
profiling and nanoLC-MS/MS analysis’. 
 
2.2.27 2D BNE/SDS-PAGE 
Enriched membranes from isolated mouse ventricular cardiomyocytes were prepared as 
described under ‘Membrane solubilization for blue native gel electrophoresis’. Briefly, 50 µg of 
total membranes were solubilized with 6 g digitonin /g protein for 45 min at 4 °C and cleared 
for 20 min at 20000 x g at 4 °C. The supernatant was supplemented with 1:10 coomassie blue 
solution and 1:10 [50%] glycerol. The solubilized membranes were applied on a Native PAGE 
3-12% Bis-Tris Protein gel (Thermo Fisher) and separated at 150 V for 60 min in ‘dark blue’ 
cathode buffer (Thermo Fisher) and at 250 V for additional 60 min using ‘light blue’ cathode 
buffer (Thermo Fisher). The electrophoresis was carried out at 4 °C. After the run BN-gel lanes 
were subjected to immunoblotting or separated in the second dimension on a 4-20% Tris-
Glycine gel (2D-well, Thermo Fisher). Before that, the BN-gel lane was equilibrated in 1% SDS, 
diluted in dH2O, for 30 min at room temperature. The BN-gel lane was cut to size, subjected 
to the 2D-well, and separated at constant 125 V for 90 min at room temperature. After the 
membranes were separated in the second dimension, the SDS-gel was subjected to 
immunoblotting on PVDF membranes at 100 V for 2 h at 4 °C, as described under 
‘Immunoblotting’. 
 
2.2.28 Mass spectrometry 
Mass spectrometry analyses were performed by Dr. Christof Lenz, Prof. Henning Urlaub and 
the Proteomics Service Unit (University Medical Center Göttingen). 
 
2.2.29 APEX2 proximity labeling and nanoLC-MS/MS analysis for quantitative 
mass spectrometry 
Samples were reconstituted in 1x SDS sample buffer and separated on 4-12 % Bis-Tris 
minigels (NuPAGE Novex, Thermo Fisher) using half of the gel length. Gels were stained with 
Coomassie Blue in order to separate individual protein lanes. Each lane was cut into 11 equal 
pieces. Gel slices were washed, reduced with 10 mM dithiothreitol (DTT, Sigma-Aldrich), 
alkylated with 55 mM 2-iodoacetamide (Sigma-Aldrich), and trypsin-digested with the 
(sequencing grade, Promega) overnight. After trypsin digestion, peptide mixtures were 
extracted, dried in a SpeedVac (Eppendorf), reconstituted in 2% acetonitrile/0.1% formic acid/ 
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(v:v) and prepared for nanoLC-MS/MS as described previously59. 
For mass spectrometric analysis samples were enriched on a self-packed reversed phase-
C18 precolumn and separated on an analytical reversed phase-C18 column using a 30 min 
linear gradient of 5-35 % acetonitrile/0.1% formic acid (v:v) at 300 nl min-1. The eluent was 
analyzed on a Q Exactive HF-X hybrid quadrupole/orbitrap mass spectrometer (ThermoFisher 
Scientific, Dreieich, Germany) equipped with a FlexIon nanoSpray source and operated under 
Excalibur 2.5 software using a data-dependent acquisition method. Each experimental cycle 
was of the following form: one full MS scan across the 350-1600 m/z range was acquired at a 
resolution setting of 70,000 FWHM, and AGC target of 1*10e6 and a maximum fill time of 60 
ms. Up to the 12 most abundant peptide precursors of charge states 2 to 5 above a 2*104 
intensity threshold were then sequentially isolated at 2.0 FWHM isolation width, fragmented 
with nitrogen at a normalized collision energy setting of 25%, and the resulting product ion 
spectra recorded at a resolution setting of 17,500 FWHM, and AGC target of 2*10e5 and a 
maximum fill time of 60 ms. Selected precursor m/z values were then excluded for the following 
15 s. Two technical replicates per sample were acquired. 
 
2.2.30 APEX2 proximity labeling data processing 
Raw data were processed using MaxQuant Software version 1.5.7.4 (Max Planck Institute for 
Biochemistry, Martinsried, Germany). Proteins were identified against a UniProtKB-derived 
rattus norvegicus protein sequence database (v2018.02, 37830 protein entries) along with a 
set of common lab contaminants. The search was performed with trypsin as enzyme and 
iodoacetamide as cysteine blocking agent. Up to two missed tryptic cleavages and methionine 
oxidation as a variable modification were allowed for. Instrument type ‘Orbitrap’ was selected 
to adjust for MS acquisition specifics. The Arginine R10, R6 and Lysine K8, K6 labels including 
the ‘Re-quantify’ option were specified for relative protein quantitation. For identification of 
APEX2 biotinylated proteins, the normalized and log2 transformed ratios of APEX2-PLN versus 
APEX2-PLNΔ(1-29) or eGFP were calculated by MaxQuant Software. Only proteins identified 
in all technical and biological replicates were used for analysis. Positive enriched biotinylated 
proteins were evaluated for statistical significance p<0.05 by one sample z-test using Microsoft 
Excel software. For visualization, scatter plots of APEX2-PLN / APEX2-PLNΔ(1-29) ratios t on 
the X-axis and APEX2-PLN / eGFP ratios on the Y-axis were generated with Prism version 




2.2.31 Gene enrichment analysis 
133 APEX2-PLN enriched proteins were enriched for their biological functions using 
ToppGene Suite tool ToppFun (default setting: FDR correction, p value cut off at 0.05 and 
gene limit set between and including 1 and 2000 per pathway)60. 
 
2.2.32 Complexome profiling and nanoLC-MS/MS analysis 
Complexome profiling and mass spectrometry are part of and were performed as published by 
Alsina et al.61.  A digitonin solubilized, enriched membrane fraction of isolated cardiomyocytes 
from PLN WT and KO mice were separated on a blue native 4-13% gradient gel as described58. 
Gel lanes were cut in 60 equal pieces.  
After washing, gel slices were reduced with 10 mM dithiothreitol (DTT, Sigma-Aldrich), 
alkylated with 55 mM 2-iodoacetamide (Sigma-Aldrich), and trypsin-digested (sequencing 
grade, Sigma-Aldrich) overnight. After trypsin,digestion, peptide mixtures were then extracted, 
dried in a SpeedVac (Eppendorf), reconstituted in 2% acetonitrile/0.05 % TFA acid/ (v:v) and 
prepared for nanoLC-MS/MS as described previously59. 
For mass spectrometric analysis samples were enriched on a C18 precolumn (Dionex 5 x 
0.3mm ID) and separated on an analytical reversed phase-C18 column (0.075 mm ID x 300 
mm, Reprosil-Pur 120 C18-AQ, 3 μm, Dr. Maisch) using a 46 min linear gradient of 5-40 % 
buffer B (80% acetonitrile/0.08% formic acid (v:v)) at 300 nl min-1). The eluent was analyzed 
on a Q Exactive HF-X hybrid quadrupole/orbitrap mass spectrometer (ThermoFisher Scientific, 
Dreieich, Germany) equipped with a FlexIon nanoSpray source and operated under Xcalibur 
4.1.31.9 software using a data-dependent acquisition method. Each experimental cycle was 
of the following form: one full MS scan across the 350-1600 m/z range was acquired at a 
resolution setting of 60,000 FWHM, and AGC target of 1*10e6 and a maximum fill time of 50 
ms. Up to the 30 most abundant peptide precursors of charge states 2 to 6 above a 2*10e4 
intensity threshold were then sequentially isolated at 1.4 FWHM isolation width, fragmented 
with nitrogen at a normalized collision energy setting of 30%, and the resulting product ion 
spectra recorded at a resolution setting of 15,000 FWHM, an AGC target of 2*10e5 and a 
maximum fill time of 54 ms. Selected precursor m/z values were then excluded for the following 
20 s. Two technical replicates per sample were acquired.  
 
2.2.33 Complexome profiling data processing 
All raw data were processed using MaxQuant Software version 1.6.0.1 (Max Planck Institute 
for Biochemistry, Martinsried, Germany). Proteins were identified against a UniProtKB-derived 
Mus musculus protein sequence database (v2016.04) along with a set of common lab 
39 
 
contaminants. The search was performed with trypsin as enzyme and iodoacetamide as 
cysteine blocking agent. Up to two missed tryptic cleavages and methionine oxidation as a 
variable modification were allowed for. Instrument type ‘Orbitrap’ was selected to adjust for MS 
acquisition specifics. Two technical replicates were measured and averaged, and protein 
abundance migration profiles were normalized considering multiple profiles, that is, taking into 
account intensity values from all slices. Each protein migration profile was maximum 
normalized, over PLN WT and KO, and colored in the given look up table using Microsoft Excel 
software. Data cluster analysis was performed by cluster 3.0 software62 with average linkage 
and uncentered Pearson correlation. 
 
2.2.34 Statistical analysis 
Data were represented as mean ± standard error of the mean (SEM). The unpaired two-tailed 
students t-test was used, considering a p-value of less than 0.05 as statistically significant. For 
APEX2 proximity labeling data analysis, the z-test was used testing against ‘0’ and a p-value 





3 Identification of novel phospholamban protein 
interactions by complexome profiling 
3.1 Introduction 
Proteins are regulators and effectors involved in all cellular processes. Through protein-protein 
interactions they can elicit multiple and complex regulatory functions that depend on their 
interactions, and organization in protein complexes. Depending on the stability and 
environment of a specific complex, its protein components can be isolated and characterized 
by classical biochemical methods, i.e. by affinity purification63. More difficult is the 
characterization of rare complexes, mainly based on transient or labile protein-protein 
interactions. Recently, there have been developed several methods for the analysis of labile 
protein complexes, i.e. yeast-two-hybrid64 or proximity-dependent protein labeling in living 
cells65,66,67. One of these methods is the APEX2 proximity labeling54 which will be subject to 
chapter II of this thesis for the identification of novel PLN interacting proteins in 
cardiomyocytes. Although these methods are successfully applied68–70,71, they rely on genetic 
expression strategies, which change the endogenous environment and potentially the 
interaction behavior of a protein of interest. A recently developed method to directly identify 
the components of labile protein-protein interactions is called complexome profiling72,73,74. This 
method is based on subcellular fractionation and extraction under native conditions, while 
membranes can be analyzed using non-ionic detergents. The ‘complexome’ of biological 
membranes, total cell or tissue homogenates can be fractionated by blue native gel 
electrophoresis75,76,58, which provides sufficient separation in the mass range of 10 kDa to 10 
MDa76. For complexome profiling, BNE lanes are cut in 60 (or more) even slices, subjected to 
tryptic digestion, and analyzed by label-free mass spectrometry (Figure 6). More than 100 
proteins per gel slice can be detected and quantified at the same time. Since not every protein 
will have the same abundance in every gel slice, abundance profiles are generated for all 
detected proteins and visualized by heatmap (Figure 6). Similar migration profiles can be 





Figure 6 Complexome profiling workflow for cardiac membranes 
Isolated membranes from cardiac samples were solubilized and separated by blue native gel 
electrophoresis (BN-PAGE). Gel lanes are cut in equal slices and subjected to tryptic digestion. Peptides 
were analyzed by mass spectrometry (LC-MS/MS) and processed using MaxQuant software. Protein 
intensities are maximum normalized for all slices showing migration profiles as heatmap and line profiles 
for illustration, exemplary for respiratory chain complex I, III, and IV. 
 
For the analysis of native cardiac protein complexes and potentially novel interaction partners 
of PLN, total membranes of mouse WT and PLN knockout isolated ventricular cardiomyocytes 
were subjected to complexome profiling. In contrast to the prevailing models, a conceptually 
new complex comprised of RyR2 and PLN/SERCA2a has been identified61. This work is part 
of a published manuscript, which identified PPP1R3A as a novel PP1-regulatory subunit within 
the RyR2 complex in addition to the previously established PLN/SERCA2a complex 
suggesting a new co-regulatory mechanism. 
 
Also, complexome profiling data revealed by hierarchical cluster analysis the sarcolemmal 
membrane-associated protein (SLMAP) as a potential novel interacting protein of PLN. SLMAP 
is a tail-anchored membrane protein initially identified in cardiac membranes78,79. The SLMAP 
gene encodes three major isoforms, which are further transcribed by alternative splicing 
(Figure 7)78,79. SLMAP1 is predominantly expressed in cardiac and slow-twitch muscles, 
whereas SLMAP3 is expressed ubiquitously, e.g. in heart, brain and skeletal muscle78,79. All 
isoforms commonly share a leucine zipper amphipathic motif involved in dimerization and 
protein interactions. Furthermore, coiled-coil carboxyl hydrophobic segments are predicted for 
the cytosolic domain of SLMAPs. Additionally, several putative phosphorylation domains have 
been identified for different kinases, i.e. casein kinase II79 or PKC and PKA78. The largest 
SLMAP3 isoform has a unique N-terminal stretch harboring the forkhead-associated domain 







































express either one of two transmembrane domains (TM1 or TM2) by alternative splicing that 
may influence subcellular localization81,79.  
SLMAP has been studied previously in skeletal muscle development and the organization of 
the excitation-contraction (E-C) coupling apparatus82. SLMAP gene mutations have been 
recently associated with the Brugada syndrome and defective trafficking of the cardiac NaV1.5 
channel to the plasma membrane in cardiomyocytes83,84. Single SLMAP isoform 
overexpression in mice showed that SLMAP1 leads to reduced protein expression of RyR2 
and SERCA2a85, and SLMAP3 a regulator of cardiomyocyte contraction is86. Still, the precise 
functional role of SLMAP in the heart needs to be elucidated. This work describes a previously 
unknown interaction of SLMAP with PLN, the functional implications of which warrant further 




Figure 7 Topology of the sarcolemmal membrane-associated protein SLMAP1-3 isoforms 
Three SLMAP isoforms transcribed by alternative splicing are translated into tail-anchored multi-domain 
membrane proteins. They differ through their coiled-coil cytosolic domains (CC), which facilitate protein-

















3.2.1 Isolation and solubilization of cardiac membranes for BN-PAGE 
To investigate native protein complexes, membranes from isolated ventricular 
cardiomyocytes56 were enriched. To identify specifically PLN interacting proteins, the 
enrichment of membranes from the sarcoplasmic reticulum (SR) was intended. Following 
protocol I (Figure 8A)87, a clear separation between the membrane proteins PLN, SERCA2a 
and CAV3, and the soluble protein GAPDH was observed (Figure 8B). After 15.000 x g 
centrifugation, the soluble fraction still contained SR and sarcolemmal (SL) proteins, which 
lead to protocol II. (Figure 8A). There, increased speed (100.000 x g) was used to collect total 
cardiac membranes (Figure 8C). The soluble fraction contained after the centrifugation at 
100.000 x g no detectable SERCA2a and not pelleted pentameric PLN and CAV3. We initially 
aimed to separate the mitochondria at 9.000 x g and enrich only SR and SL membranes. By 
immunoblotting, we also detected mitochondrial proteins in the 100.000 x g membrane fraction 





Figure 8 Membrane isolation from mouse ventricular cardiomyocytes 
A, Workflow for the separation of sarcoplasmic reticulum membranes by differential centrifugation. After 
mechanical disruption and resuspension in detergent-free sucrose buffer, cell debris and nuclei were 
removed at 3.000 x g. To remove mitochondria, the peri-nuclear fraction (PNF) was centrifuged at 9.000 
x g. The supernatant was finally centrifuged at I.) 9.000 x g or II.) 100.000 x g to obtain SR membranes.  
B-C, Immunoblots showing intermediate steps of the enriched membranes by differential centrifugation 
from isolated ventricular cardiomyocytes following protocol I (B) or II (C). 
 
Limiting by incomplete separation of mitochondrial from SR membranes and loss of SR and 
SL membranes at 9.000 x g (Figure 8B,C), total membrane fractions were used for further 
analysis (Figure 9A). Cardiomyocytes were lysed in detergent-free sucrose buffer using a 










































































gel electrophoresis (BN-PAGE), membranes were solubilized (Figure 9B) as follows. To better 
define the stability and the nature of cardiac protein complexes, two different detergents were 
tested. Digitonin solubilized membranes showed stronger signals for PLN and SERCA2a after 
BN-PAGE and immunoblotting compared to n-dodecyl ß-D-maltopyranoside (DDM), indicating 
sufficient solubilization (Figure 9C). Furthermore, PLN and SERCA2a may reside in 
macromolecular complexes, while only SERCA2a remains both in WT and PLN KO complexes 
(Figure 9D). Taken together, for the complexome profiling analysis total cardiac membranes 
of WT and PLN KO ventricular cardiomyocytes were isolated by ultracentrifugation. Digitonin 





Figure 9 Membrane isolation and solubilization from ventricular cardiomyocytes 
A, Workflow of the final membrane isolation protocol for isolated mouse ventricular cardiomyocytes. 
After mechanical disruption and resuspension in detergent-free sucrose buffer, cell debris and nuclei 
were removed at 3.000 x g. After that, the peri-nuclear fraction (PNF) was centrifuged at 100.000 x g for 
60 min.  B, Workflow of the membrane solubilization before BN-PAGE. 100.000 x g membranes were 
solubilized with 6 g digitonin per gram protein. Un-solubilized proteins were removed at 21.000 x g. C, 
Immunoblots of digitonin or n-dodecyl ß-D-maltopyranoside (DDM) solubilized ventricular membranes 
separated by 4-9% BNE gradient gel showing different signal intensities for PLN and SERCA2a. D, 
Immunoblots of digitonin solubilized membranes from WT and PLN KO ventricular cardiomyocytes 







































































3.2.2 Complexome profiling analysis of native cardiac membranes 
For complexome profiling, mouse WT and PLN KO ventricular cardiomyocyte (VCM) 
membranes were digitonin-solubilized and separated by BN-PAGE. Each BN lane was cut in 
60 gel slices for in-gel tryptic digestion and subjected to mass spectrometry analysis (LC-
MS/MS) (Figure 10A). For each detected protein, intensity profiles obtained by MaxQuant 
software were processed and analyzed. Mass spectrometry sample preparation and data 
acquisition were carried out by Dr. Christof Lenz, Prof. Henning Urlaub, and the Proteomic 
Service Unit (University Medical Center Goettingen). 
The binding of the anionic dye coomassie to hydrophobic mainly membrane proteins induces 
a charge shift and allow their migration to the anode. Some but not all soluble proteins have 
basic amino acid residues and bind coomassie as well88. For quality control and mass 
calibration, soluble and integral membrane proteins, and protein complexes with known 
molecular weight were assigned to BN-gel slice number of their abundance (Figure 10B,C). 
This calibration showed a linear separation of soluble and membrane proteins and indicates a 





Figure 10 BN-PAGE gel for complexome profiling and mass calibration 
A, Blue native gel lanes from WT and PLN KO mouse VCM. Indicated 60 slices were cut and subjected 
to tryptic in-gel digestion and mass spectrometry. For mass calibration of WT (B) and PLN KO (C), the 
known molecular weight88 of soluble and integral membrane proteins and protein complexes were 
plotted against their slice number. in blue native electrophoresis. Soluble and membrane protein show 
different migration behavior within the BN-gel based on their hydrophobic surface and affinity for 
coomassie. Modified from Alsnia et al.61 
 
Furthermore, complexome profiling was previously used for the characterization of 
mitochondrial OXPHOS complexes74,73,89. Due to the high abundance of mitochondrial proteins 
in the total cardiac membrane fraction, mitochondrial protein complexes were used as well-
established quality control. Heat maps and migration profiles of WT and PLN KO VCM 
membranes showed the abundance of monomeric complexes as complex II, IV and V. Higher 
complexes as the dimer of complex III (III2) and multimer of complex IV (IVn) as well as 
supercomplexes with complex I, III and IV were identified. Apparently, PLN KO mitochondrial 
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Figure 11 Complexome profiling of OXPHOS complexes 
A+B, Heat maps of OXPHOS complexes in WT and PLN KO VCM were used as methodical quality 
control and for mass calibration. Respiratory chain complexes are indicated as complex I (I), complex II 
(II), complex V (V), complex III (III2, dimer), domplex IV (IV, IVn, multimer), and supercomplexes (S0-
Sn)74. C-F, Average abundance of all OXPHOS subunits presented in heat maps and migration profiles 
in WT and PLN KO VCM. Modified from Alsnia et al.61 
 
Data clustering revealed the Na,K-ATPase 1-1 complex90 together with its regulator 
phospholemman (PLM) (Figure 12A)91. Remarkably, different states of the Na,K-ATPase 
complex were identified through a mass shift, namely the active complex (1-1) or inhibited 
WT PLN KO
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by PLM binding (1-1 / PLM)  (Figure 12A, inset). This example shows the sensitivity and 
resolution of this method to distinguish between molecular complexes with different functional 
states. Furthermore, PLN and SERCA2a showed a similar migration pattern and are part of 
macromolecular complexes with increasing abundance in the high molecular range (Figure 
12B). Even PLN monomers and pentamers were captured. Interestingly, SERCA2a complexes 
were disrupted in PLN KO cardiomyocytes61. 
 
 
Figure 12 Complexome profiling of mouse ventricular cardiomyocyte membranes 
Heat maps representing the complexome profiling data of mouse ventricular cardiomyocytes (VCM). 
Colors indicate the intensity gradient (look-up-table) by its relative abundance. The same data were 
plotted as line profiles showing the molecular weight on a logarithmic scale versus normalized protein 
abundance. A, In WT VCM, Na,K-ATPase subunits α1 and β1 showed the same migration pattern, 
whereas its regulator phospholemman (PLM) showed two main peaks. The inset shows the mass range 
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from 0 to 350 kDa were a mass shift of the Na,K-ATPase complex (α1-β1) due to the binding of PLM 
can be recognized (α1-β1 / PLM). B, WT and PLN KO complexome profiling data for PLN and 
SERCA2a. Mono- and pentameric PLN and monomeric SERCA2a (arrowheads) were detected at the 
expected molecular mass and showed a similar migration pattern at the high molecular range. In PLN 
KO, SERCA2a distribution was altered with a reduced signal. Figures were modified from Alsina et al.61. 
 
Further analysis showed that protein phosphatases and kinases could be identified by 
complexome profiling (Figure 13). The catalytic subunits  and  of the protein phosphatase 1 
(PP1) are abundant in the same gel slice, whereas the regulatory subunit PPP1R3A was found 
in the high molecular weight range. It is interesting to note that this complex was disrupted in 
PLN KO cardiomyocytes61. Also, the protein kinase A, which phosphorylates PLN92 was 
detected in an inactive tetramer composed of two catalytic C- subunits and the two regulatory 
RI- and RII- subunits (Figure 13B,E)93,94. Upon cAMP binding93, the catalytic subunits are 
released and active, reflecting the indicated peak at 30-40 kDa (Figure 13B,E). The second 
kinase which phosphorylates PLN is the calcium/calmodulin-dependent protein kinase 2 
(CaMK2). In addition to the predominant cardiac-specific isoform CaMK295, CaMK2 was 




Figure 13 Complexome profiling of kinase and phosphatase distributions 
WT and PLN KO complexome profiling data of mouse ventricular cardiomyocytes (VCM). A+D, Protein 
phosphatase 1 (PP1) catalytic subunits α and  show a different migration pattern compared to the 
regulatory subunit 3A (PPP1R3A). Ablation in PLN resulted in reduced abundance and altered 
distribution of PPP1R3A in high molecular weight complexes. The figure was modified from Alsina et al. 
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kDa (active) and bound as a dimer to the regulatory subunits RI-α and RII-α in a complex at >100 kDa 
(inactive). In PLN KO, C-α distribution is altered (E). C+F, Calcium/calmodulin-dependent protein kinase 
2 (CaMK2) subunits α and  were found in high molecular weight complexes >1000 kDa and show 
increased signals in PLN KO. 
 
Additionally, complexome profiling revealed PPP1R3A together with RyR2 and the 
PLN/SERCA2a in a complex suggested by overlapping migration profiles (Figure 14). 
Interestingly, these high molecular weight complexes are disrupted in the absence of PLN. 
This finding is part of the publication by Alsina et al. (‘Loss of Protein Phosphatase 1 Regulatory 
Subunit PPP1R3A Promotes Atrial Fibrillation’ Circulation 2019)61.  
In general, these data show that complexome profiling is a promising application for the 
analysis of cardiac macromolecular protein complexes. A conceptually new protein complex 
that includes PLN, SERCA2 and RyR2 have been identified, including PPP1R3A as co-
regulatory mechanism for PP1 targeting61.  
Importantly, hierarchical cluster analysis of the migration profiles revealed sarcolemmal 
membrane-associated protein (SLMAP) as a potential new interacting protein of PLN, co-





Figure 14 Complexome profiling shows novel ‘SR Ca2+ cycling complex’ 
WT and PLN KO complexome profiling data of mouse VCM. A+D, Heat maps representing the 
complexome profiling data for PLN, SERCA2a, RyR2, and PPP1R3a. Colors indicate the intensity 
gradient of normalized abundance (look-up-table). B+E, The same data were plotted as line profile for 
PLN, SERCA2a and PPP1R3A showing the molecular weight versus normalized protein abundance. 
Arrows indicate the overlap of abundance profiles suggesting a macromolecular complex, also together 
with RyR2 (C+F), whereas PLN KO leads to the reduced abundances and the loss of high molecular 
weight complexes >800 kDa. Modified from Alsnia et al.61 
 
3.2.3 SLMAP forms high molecular weight complexes 
The analysis of native membrane complexes by blue native gel electrophoresis is a state-of-
the-art method to analyze known protein-protein interactions, track changes but also to 
characterize novel protein complexes. As described in the previous chapter, PPP1R3A was 
shown to bind to the PLN/SERCA2a complex and the ryanodine receptor 2 channel 
macromolecular protein assemblies by complexome profiling in line with additional 
experimental data61. 
Additionally, hierarchical cluster analysis from mouse ventricular cardiomyocytes revealed that 
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complex (Figure 15A). Upon PLN ablation, the SLMAP signals were increased and showed 
higher similarity to the SERCA2a profile compared to wildtype (Figure 15B). At the same time, 
SERCA2a distribution was altered and decreased as described before61. SLMAP is a tail-
anchored transmembrane protein78, confirming the SLMAP enrichment in membrane fractions 
of WT and PLN KO ventricular cardiomyocytes (Figure 15C). SLMAP can give rise to several 
isoforms as a result of alternative splicing78,79. In mass spectrometry, only peptides shared by 
all isoforms are detected the coiled-coil domains 3 and 4 particularly (Figure 7). Because LC-
MS/MS cannot discriminate between the isoforms, we quantified the abundance of different 
SLMAP isoforms in high molecular weight complexes by 2D BNE/SDS-PAGE experiments 
(Figure 15D). Immunoblotting showed SLMAP isoforms in a heteromeric complex at ~200 kDa 
in the high molecular range (>200 kDa). Taken together, all SLMAP isoforms are abundant in 
high molecular weight complexes and show a similar migration profile within the BN gel, 




Figure 15 SLMAP isoforms form high molecular weight complexes 
A, Heat maps representing the complexome profiling data for PLN, SERCA2a, and SLMAP of mouse 
WT and PLN KO ventricular cardiomyocytes (VCM). Colors indicate the intensity gradient of normalized 
abundance (look-up-table). Membranes were digitonin-solubilized, separated on a 4-13% blue native 
(BN) gel and subjected to mass spectrometry (LC-MS/MS). Data were maximum normalized over WT 
and PLN KO signals. B, The same data were plotted as line profile showing the molecular weight versus 
normalized protein abundance. In mouse WT VCM, SLMAP showed a similar migration pattern with the 
PLN/SERCA2a complex. Ablation in PLN KO resulted in an increase of the SLMAP signals compared 
to WT, whereas the SERCA2a distribution was altered with a reduced signal. C, Detergent-free 
perinuclear fractions (PNF) of mouse WT and PLN KO ventricular cardiomyocytes were ultracentrifuged 
at 100.000 x g and samples separated on a 4-20% SDS gel. Immunoblot showing enrichment of SLMAP, 
SERCA2a, and PLN in the membrane fractions (P). GAPDH was used as a cytosolic marker protein 
enriched in the supernatant (S). Arrowheads indicate the different SLMAP isoforms. D, Immunoblotting 
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isoforms in mouse WT VCM. For this, enriched membranes were digitonin solubilized, separated in the 
first dimension by BNE, and in the second dimension by SDS gradient gel under denaturing conditions. 
SLMAP isoforms form a heteromeric complex at ~200 kDa and are present in higher molecular weight 
complexes (>200 kDa).  
 
3.2.4 SLMAP localization and PLN proximity in mouse ventricular 
cardiomyocytes 
As the localization of SLMAP depends on its transmembrane domain and has been localized 
to different subcellular compartments81,96, we immunolabeled SLMAP for confocal and STED 
co-immunofluorescence imaging with Caveolin 3 (CAV3) and PLN, respectively. Whereas 
confocal microscopy showed a transversal striated pattern for SLMAP, STED nanoscopy 
resolved clearly separated SLAMP and CAV3 signals, i.e. with no signal overlap, in WT and 
PLN KO mouse ventricular cardiomyocytes (Figure 16A). In contrast, SLMAP signals are 
immediately adjacent and surrounded by PLN signals indicating localization in the 





Figure 16 SLMAP shows a transversal striated pattern in mouse ventricular tissue 
Confocal and STED co-immunofluorescence imaging was used for mouse WT and PLN KO ventricular 
tissue from paraffin-embedded histological sections stained with SLMAP and CAV3 or PLN, 
respectively. Dashed boxes indicate magnified regions where STED superresolution nanoscopy 
resolved a separated localization of SLMAP and CAV3 (A). In contrast, the SLMAP signals were 
immediately adjacent to and surrounded in subcellular domains by PLN (B). In PLN KO, the PLN 
antibody showed signals not present in WT, which were related to unspecific mitochondrial background. 
Scale bars: top 10 μm; Confocal microscopy 1 μm; STED nanoscopy 1 µm; STED magnification 
200 nm.  
 
To explore the hypothesis that SLMAP and PLN can directly interact, we performed co-
immunoprecipitation experiments (Figure 17). Interestingly, all three SLMAP isoforms were 
successfully co-purified with PLN. In summary, these data confirm close proximity of PLN and 
















Figure 17 SLMAP is co-purified with PLN by affinity purification 
PLN-targeted co-immuno purification (IP) of mouse ventricular tissue (WT), followed by immunoblotting, 
confirmed the protein-protein interaction between PLN and SLMAP. PLN KO ventricular tissue (KO) was 
used as a negative control. The previously established PLN-SERCA2a interaction was used as a 
positive control. Arrowheads indicate the different SLMAP isoforms and SERCA2a. Asterisks indicate 
IgG heavy chain detected by the secondary antibody. I: Input; n = 3. 
 
3.2.5 SLMAP expression is altered in PLN KO mouse hearts and cardiac 
hypertrophy 
To further explore the SLMAP abundance change observed in PLN KO (Figure 15), we 
investigated the SLMAP protein expression in ventricular heart tissue by immunoblotting. 
Quantifications confirmed the complexome profiling data by showing a significant increase in 
SLMAP1 and SLMAP3 expression in PLN KO ventricles (Figure 18A,B), whereas SERCA2a 
expression was reduced (Figure 18A,C). RyR2 was not found to change significantly on the 




















Figure 18 Mouse ventricular tissue expression of SLMAP in WT and PLN KO mouse hearts 
A, Immunoblotting of ventricular tissue lysates from PLN wildtype (WT) versus knockout (PLN KO) of 
adult mice. B, Quantifications of immunoblots normalized to GAPDH show a significant increase of 
SLMAP1 and SLMAP3 expression and total SLMAP (C) in PLN ablated tissue. In contrast, SERCA2a 
expression is significantly decreased (C). A representative GAPDH immunoblot is shown, while each 
blot was normalized to its GAPDH signal. Data represent means and ±SEM, n = 5. *P<0.05; **P<0.01; 
***P<0.001; NS: not significant, Student’s t-test. 
 
Not only PLN KO hearts but also hearts during the development of hypertrophy and heart 
failure underwent molecular changes97,55,98. It has been reported that SLMAP3 protein 
expression is increased in hypertrophic mouse hearts98. We hypothesized that all SLMAP 
isoform expression levels change during heart failure. To test this, we used a model of 
transaortic constriction (TAC) to study SLMAP expression changes during induced left 
ventricular hypertrophy in mice.  
Immunoblot experiments of WT mice revealed a significant increase of all SLMAP isoform 
protein expression four weeks after TAC (Figure 19A,B), whereas RyR2 and SERCA2a were 
significantly decreased (Figure 19A,C). PLN was not changed. Study design and sample 
preparation were carried out by Dr. Sören Brandenburg (Dept of Cardiology and Pneumology, 
University Medical Center Göttingen), and tissue lysates were kindly provided for this work. 
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Figure 19 SLMAP protein expression is increased in mouse ventricular tissue after TAC 
A, Immunoblots of ventricular tissue lysates of WT mice 4 weeks after TAC intervention. B, 
Quantification of immunoblots normalized to GAPDH shows a significantly increased expression of all 
SLMAP isoforms. In contrast, RyR2 and SERCA2a were significantly reduced after TAC. PLN 
expression was not changed significantly (C). A representative GAPDH immunoblot is shown, while 
each blot was normalized to its GAPDH signal. Data represent means and ±SEM, n=4 minimum. 
*P<0.05; **P<0.01; ***P<0.001; NS: not significant, Student’s t-test. 
 
To investigate how SLMAP protein expression changes in TAC operated PLN KO hearts, we 
performed these experiments in collaboration with the service unit of the SFB1002 (University 
Medical Center Göttingen). It has been shown that PLN KO mice can compensate against a 
sustained TAC intervention similar to WT mice97. The TAC operated PLN KO hearts showed 
a significant increase for SLMAP2 (Figure 20A,B), whereas total SLMAP was un-changed 
compared to WT sham (Figure 20C). SERCA2a expression was reduced in PLN KO, similar 
to WT hearts. RyR2 protein expression was not changed. Taken together, these data confirm 
the increased expression of SLMAP in PLN KO and TAC hearts by RNA microarray and 
immunoblotting. Importantly of note that the group size n=2 of PLN KO after TAC intervention 
was not sufficient for statistics. 
 



















































































































Figure 20 SLMAP protein expression is unchanged in PLN KO ventricular tissue after TAC 
A, Immunoblots of ventricular tissue lysates show sham versus TAC 4 weeks after the intervention of 
WT and PLN KO mice. B, Quantification of immunoblots normalized to GAPDH show significantly 
increased expression of SLMAP2 and SLMAP3 in WT after TAC. In PLN KO, only SLMAP2 was 
significantly increased, whereas SLMAP1 and SLMAP3 show no changes compared to sham WT. C, 
SERCA2a expression was reduced after TAC in WT and PLN KO, whereas RyR2 and PLN expression 
were not changed significantly. Total SLMAP expression was only significantly increased in WT hearts 
after TAC. A representative GAPDH immunoblot is shown, while each individual blot was normalized to 
its GAPDH signal. Data represent means and ±SEM, n(Sham WT) = 5, n(TAC WT) = 5, n(TAC PLN 
KO) = 2, gender mixed mice. *P<0.05; **P<0.01; ***P<0.001; NS: not significant, Student’s t-test. 
 
3.2.6 SLMAP in human iPSC-derived cardiomyocytes 
To investigate the expression and localization of SLMAP in iPSC-derived cardiomyocytes we 
performed immunoblots, confocal and STED superresolution microscopy (Figure 21). 
Immunoblots showed robust and increasing expression of SLMAP isoforms after 60 and 90 
days of differentiation in iPSC-derived cardiomyocytes (iPSC-CM) (Figure 21A). Co-
immunofluorescence staining revealed SLMAP signals, adjacent and surrounded by PLN and 

































































































































































































































Figure 21 SLMAP is expressed in human iPSC-derived cardiomyocytes 
A, Immunoblotting of human iPSC-derived cardiomyocytes (iPSC-CM) after indicated days of 
differentiation. SLMAP and PLN are robustly expressed upon differentiation. Tubulin was used as an 
expression marker. Arrowheads indicate SLMAP isoforms. B, Confocal and STED co-
immunofluorescence imaging of SLMAP with PLN or SERCA2a in 60 days differentiated human iPSC-
CM. STED magnifications show clustered signals for SLMAP and overlap partially with PLN or 
SERCA2a signals. Scale bars: top 10 μm; Confocal microscopy 1 μm; STED nanoscopy 1 µm; STED 
magnification 200 nm. 
 
Differentiation and cultivation of human iPSC were carried out by Dr. Lukas Cyganek and the 
Stem Cell Unit (University Medical Center Göttingen). 
In summary, SLMAP is sufficiently expressed in human iPSC-CM and will be targeted by 
CRISPR/Cas9 to generate an SLMAP knockout and study the potentially functional complex 






























The exploration of novel PLN interaction partners is of high importance to understand how it is 
molecularly regulated and to develop rationales for new therapeutic interventions for patients 
and animals with heart disease. 
This study was designed to identify potential new protein interactions of phospholamban and 
to explore native protein complexes in cardiac membranes. A recently developed complexome 
profiling approach72,74,73 was applied to study native protein complexes involved in muscle 
contraction in cardiac membranes from isolated mouse ventricular cardiomyocytes.  
Cardiac membranes were isolated under native conditions and separated by blue native gel 
electrophoresis58, followed by mass spectrometry analysis59. Abundance profiles showed the 
migration of each detected protein in the gel and revealed several macromolecular complexes.  
For quality control, the mitochondrial OXPHOS complexes were analyzed as to their assembly 
into so-called supercomplexes is well described74,89. 
As a result, PLN and SERCA2a were found to be abundant in macromolecular complexes, 
whereas these complexes were altered with reduced abundance upon PLN ablation. 
Furthermore, a conceptually new macromolecular complex comprised of RyR2 and the 
PLN/SERCA2a complex has been identified61. This complex was accompanied by the 
regulatory subunit PPP1R3a targeting the protein phosphatase 1 to PLN99 and the RyR2 
protomers of the tetrameric channel61. 
Additionally, a potentially new interacting partner of PLN was identified by migration profile 
clustering, the sarcolemmal membrane-associated protein (SLMAP). Together with STED 
superresolution microscopy and co-immunoprecipitation experiments, an association of 
SLMAP and PLN is suggested. Furthermore, in PLN KO heart tissue, SLMAP expression was 
found to be increased, as well as in a cardiac hypertrophy mouse model after 4 weeks of 
transaortic constriction. Taken together, a potential role during hypertrophic remodeling and 
heart failure development was identified for SLMAP. In order to analyze a potential role of 
SLMAP in intracellular Ca2+-cycling, ß-adrenergic stimulation, and contraction, a 
CRISPR/Cas9 targeted knockout in human induced pluripotent stem cell-derived 
cardiomyocytes was designed for future analysis. 
 
3.3.1 Isolation and solubilization of cardiac membranes for BN-PAGE 
The recently developed bottom-up proteomics approach complexome profiling72,74,73 was 
applied to identify PLN protein interactions in cardiac membranes. In order to enrich cardiac 
SR membranes from isolated ventricular cardiomyocytes, differential centrifugation87 was used 
to separate different cellular compartments and membrane organelles. Sample preparation is 
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critical for protein complex stability, retrieval, and gel separation quality100. To maintain stable 
protein complexes, a detergent-free homogenization buffer was used. However, under these 
conditions, a sufficient SR separation from other cell compartments was not possible. This is 
not unexpected, as mitochondria are highly abundant in cardiomyocytes101, and physical 
SR/ER-mitochondria contacts known as mitochondria-associated ER membranes (MAM), with 
physiological roles, are present102. Finally, total cardiac membranes were used for 
complexome profiling, taken into account that the complexity of the sample may lead to more 
missing peak volume values and reduced dynamic range100. As this method was established 
for mitochondrial complex analysis73,74, the respiratory complexes were used as internal 
standard and quality control.  
Furthermore, the choice of detergent has a substantial impact on complex solubilization 
efficiency, membrane complex representation, and stability103. DDM and digitonin are non-
ionic, relatively mild detergents that may maintain the native association between several 
proteins and are, thus, widely used for blue native separation and mass 
spectrometry72,74,73,104,105. For each protein of interest and biological starting material, the 
preservation of protein interactions may vary between detergents. Therefore, cardiac 
membrane solubilization with digitonin was used, confirming PLN and SERCA2a abundance 
in high molecular weight complexes. 
In order to separate protein complexes from biological membranes, blue native gel 
electrophoresis was used, reproducing a mass range from 10 kDa to 10 MDa58. This well-
established method allows for separation according to protein complex size rather than 
charge/mass ratio in the BN gradient gel58. Here, the BN-gel showed a clear separation for 
solubilized cardiac membrane protein complexes. Of note, there may be differences in gradient 
gel mixture, BNE running conditions, and cutting of gel pieces. In order to achieve higher 
reproducibility with a similar resolution in protein complex separation, an alternative approach 
is size exclusion chromatography followed by mass spectrometry analysis106. 
 
3.3.2 Complexome Profiling analysis of native cardiac membranes 
Complexome profiling has been used successfully for the identification of new protein-protein 
interactions74,87,89 or protein-assemblies and their intermediates89. It is also used to identify 
protein complex changes in patients with mitochondrial diseases107. Thus, complexome 
profiling is a suitable method for the analysis of complexes and protein-protein interactions of 
multiple proteins at the same time. The analysis of cardiac membranes from PLN WT and KO 
mouse ventricles revealed unexpected changes in migration profiles and protein abundances 
in macromolecular complexes.  
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For quality control, mass calibration of soluble and membrane proteins established a linear 
correlation indicating a sufficient separation of proteins within the BN gel. Additionally, 
mitochondrial respiratory chain complex assemblies were detected as described previously74,89 
without alterations between PLN WT and KO. This finding is in good agreement with normal 
heart rates in PLN KO mice with no reported mitochondrial defects36. 
Analogous to SERCA2a regulation by PLN, the Na,K-ATPase activity is regulated by the 
muscle-specific micropeptide phospholemman (PLM)91. Remarkably, different states of the 
Na,K-ATPase complex90 associated with PLM were captured by mass differences. This 
example shows the sensitivity, and resolution of this method, to distinguish between molecular 
complexes with different functional states and may, thus, allow detecting functional changes 
also in disease and therapeutic intervention models. 
Most interestingly, as expected PLN and SERCA2a are tightly associated with increased 
abundance in the high molecular weight range. This finding is quite different from the 
observations for Na,K-ATPase and PLM complex distribution, suggesting different behaviors 
for plasma membrane and SR proteins, as well as a substantial PLN/SERCA2a organization 
in macromolecular complexes. Germline PLN ablation resulted in major alterations of these 
complexes, consistent with its functional significance in the heart36. 
Furthermore, soluble proteins like protein phosphatases and kinases were identified, 
suggesting associations to membrane proteins. Protein phosphatase 1 (PP1) plays an 
essential role in calcium signaling and is targeted to RyR2 and PLN in the heart108,99,61. Here, 
not PP1, but its regulatory subunit PPP1R3A was abundant in macromolecular complexes. As 
the only detected regulatory subunit of PP1, it showed an overlap with RyR2 and the 
PLN/SERCA2a complexes. Alsina et al. could show that PPP1R3A targets PP1 not only to 
PLN but additionally to RyR261. The finding was supported by complexome profiling and 
revealed a previously unknown SR Ca2+ cycling complex comprised of RyR2 and 
PLN/SERCA2a, and each together with PPP1R3A. It is interesting to note that PLN ablation 
led to a reduced abundance of RyR2 and SERCA2a and a near total loss of PPP1R3A in the 
high molecular weight complexes. Together with STED superresolution microscopy, our data 
may support a new physically interacting and functionally co-regulated signaling nanodomain 
termed ‘SR Ca2+ cycling complex’61. It remains to be established whether this complex is 
organized by additional interactions or assembly factors. 
Moreover, the cAMP-dependent protein kinase A (PKA), which phosphorylates PLN at Ser-
1692, was detected in its inactive tetrameric and its catalytic active state93,94. PKA is targeted 
to substrates at different subcellular loci by A-kinase anchoring proteins (AKAPs)109,110. 
However, in our data PKA was not detected in macromolecular complexes, and AKAPs were 
not detected under these experimental conditions. The second kinase which phosphorylates 
PLN is the calcium/calmodulin-dependent protein kinase 2 (CaMK2). In addition to the 
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predominant cardiac isoform CaMK295, CaMK2 was detected. Both isoforms were abundant 
in macromolecular complexes, which is consistent with the reported CaMK2 targeting to SR 
membranes95. Additionally, CaMK2 signals at the high molecular weight are overlapping with 
the PLN/SERCA2a complex, which may present an additional constituent of the described SR 
Ca2+ cycling complex. 
In general, these data show that complexome profiling is a valuable application for the analysis 
of cardiac macromolecular protein complexes. A conceptually new protein complex that 
includes PLN, SERCA2, and RyR2 has been identified, including PPP1R3A as a co-regulatory 
mechanism for PP1 targeting61. 
 
3.3.3 SLMAP proximity to PLN in cardiomyocytes 
In order to identify protein-protein interactions by complexome profiling, hierarchical clustering 
was applied to group proteins in clusters based on similarities in their migration pattern. Based 
on this clustering, the sarcolemmal membrane-associated protein (SLMAP) was identified as 
potentially interacting protein in the PLN/SERCA2a complex. PLN ablation showed a higher 
abundance of SLMAP in macromolecular complexes and an overall increased signal. 
Immunoblotting confirmed a significant increase in SLMAP protein expression (SLMAP1, 
SLMAP3). Interestingly, all SLMAP isoforms were abundant in the macromolecular complexes 
suggesting a functional role. 
SLMAPs are targeted to different subcellular locations depending on their transmembrane tail-
anchored domain81,96. In contrast to earlier reports96, SLMAP was not localized in the 
sarcolemma and the T-tubular system but was present in SR membranes along transversal Z-
lines in ventricular cardiomyocytes. Surprisingly, neither changes in SLMAP localization nor its 
cell-wide distribution were apparent in PLN KO cardiomyocytes. In WT cardiomyocytes, 
SLAMP was detected immediately adjacent to PLN rich SR domains, and co-
immunoprecipitation experiments showed co-elution of all SLMAPs. These data suggested a 
proximity-based local association of SLMAP and PLN, which may contribute to a functional 
signaling complex in the SR membrane. 
 
3.3.4 SLMAP expression changes in cardiac hypertrophy 
Cardiac hypertrophy increases the risk for congestive heart failure111 and is characterized by 
reduced SERCA2a expression and thus dysregulated Ca2+ signaling in cardiomyocytes112. 
Here, the Ca2+ transport proteins RyR2 and SERCA2a showed decreased expression, 
whereas PLN showed no changes 4 weeks after transverse aortic constriction (TAC). In 
contrast, SLMAP isoforms were significantly increased at protein levels in ventricular 
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cardiomyocytes isolated 4 weeks after TAC. This confirms previous findings, showing that 
SLMAP3 protein expression was significantly increased 30 days after TAC in mice98. However, 
in human dilated cardiomyopathy ventricles, a decreased expression of SLMAP was 
reported86. This finding differs from the increased SLMAP expression we found in mice with 
induced left ventricular hypertrophy and might be explained by the advanced end-stage DCM 
post-mortem phenotype of human ventricles.  
Additionally, 4 weeks after TAC, only SLMAP2 protein expression was significantly increased 
in PLN KO hearts compared to Sham WT hearts. However, SLMAP1 and SLMAP3 protein 
levels in TAC PLN KO were equal to Sham WT. This suggests that induced ventricular 
hypertrophy in PLN KO may decrease the protein expression of SLMAP1 and SLMAP3 since 
the basic level of SLMAP in PLN KO hearts is significantly increased compared to WT. These 
results thus need to be interpreted with caution due to the small group size of PLN KO mice 
after TAC (n=2). 
 
3.3.5 SLMAP expression in human iPSC-derived cardiomyocytes 
SLMAP transcriptional expression in human induced pluripotent stem cells was found to 
significantly  increase during cardiomyocyte differentiation (day 12 vs. day 40)113. We made 
similar observations during iPSC-cardiomyocyte differentiation and maturation from day 60 to 
day 90. The increasing expression of SLMAP during maturation might also affect the 
localization in iPSC-CM. SLMAP localization was observed as subcellular clustered in 60 days 
old iPSC-CM. This contrasts with the SLMAP distribution along Z-lines in adult mouse VCMs. 
Thus, SLMAP localization may change due to maturation and increased expression levels113. 
Importantly, in iPSC-CM, SLMAP was localized in nanometric proximity to PLN and SERCA2a 
shown by STED nanoscopy (Figure 21). 
 
In summary, SLMAP was identified as a potential interacting protein by migration cluster 
analysis in complexome profiling. SLMAP was further identified as PLN interacting protein by 
co-immunoprecipitation and showed a proximal association with PLN in mouse VCM and 
human iPSC-CM by STED superresolution microscopy. In PLN KO and TAC operated WT 
mice, SLMAP protein expression was found to be significantly increased.  
It remains to be determined if the differently spliced SLMAP TM domains mediate the PLN 
binding. Furthermore, SLMAP3 has a unique N-terminal FHA domain, which can interact with 
other proteins in a phospho-dependent manner114. Hence, SLMAP3 may also interact with PLN 
through the FHA domain in a phospho-dependent manner. 
Together, these data suggest a proximity-based local association of SLMAP and PLN, which 
may contribute to a functional signaling complex in the SR membrane.  
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4 PLN targeted APEX2 proximity labeling 
4.1 Introduction 
As mentioned before, protein-protein interactions are involved in all kinds of cellular processes. 
Standard methods for the identification of protein-protein interactions frequently use in vitro 
and non-physiological conditions. Recently, new methods have been introduced for the 
proximity labeling of proteins in living cells. These techniques are based on exogenous 
enzymes that generate reactive labels that enable protein isolation and identification by mass 
spectrometry. For example, biotin was exploited as a protein label to isolate with avidin or 
streptavidin specifically. Once it has been attached covalently, biotinylated proteins can be 
captured under stringent lysis and wash conditions resulting in a higher purity of isolated 
proteins. 
For proximity-dependent biotin identification (BioID)66,67, a biotin ligase is bound to a bait-
protein for proximity labeling. Upon cellular expression, it generates reactive biotin and fuses 
it to proximal proteins with a labeling period of hours. This results in an accumulation of labeled 
proteins at a distance of approximately 10 nm to the bait protein115.  
A more rapid way to label proximal proteins is the APEX proximity labeling. It can also be 
applied in living cells and is bound to the bait protein. APEX is an engineered ascorbate 
peroxidase from soybean, which creates by its enzymatic activity short-lived radicals reacting 
with tyrosine and other electron-rich amino acids as tryptophan, cysteine, and histidine68. The 
APEX reaction creates not a history of interacting proteins like BioID but rather a snapshot by 
a short reaction pulse of 1 min54. The improved 2nd generation variant, APEX2, improved its 
reactivity and can be applied at lower concentrations65. Previously, APEX2 was successfully 
used for mapping proteomes in the intermembrane space in mitochondria68, cilia70, and also 
for dynamic approaches of G-protein coupled receptors upon stimulation71. 
For screening potential novel interaction partners of PLN, a fusion construct of APEX2 and 
canine phospholamban was designed (Figure 22A,B). To allow for the identification of 
interaction partners from the cytosol, APEX2 was tagged N-terminally to PLN.  A flexible GS 
linker maintains PLN interactions with endogenous proteins. The N-terminal epitope tag V5 
was used for detection in immunoassays. Following the expression with APEX2-PLN and the 
incubation with biotin-phenol (BP), the cells were exposed to hydrogen peroxide (H2O2) to 
initiate the enzymatic reaction54 (Figure 22C). BP is converted to the short-lived biotin-phenoxyl 
radical, which covalently labels proteins in nanometric proximity in a range from 
<20 nm116,117,118. As spatial sarcoplasmic reticulum targeted control, a truncation of PLN 
missing amino acids 1 to 29 was used (Figure 22A,B). Hence, only the transmembrane domain 
of PLN was fused to APEX2, resulting in APEX2-PLN(1-29). 
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This work showed that APEX2-PLN could be targeted to subcellular locations in 
cardiomyocytes for proximity live labeling. For a ratiometric proteomic approach, SILAC was 
established for quantification in neonatal rat cardiomyocytes (NRCMs), and potential PLN 
protein interactors were labeled. This approach has potentially important implications for 
further understanding of the regulation of SR Ca2+ uptake in the heart. 
 
 
Figure 22 Proximity proteomics of canine phospholamban for the identification of novel 
interaction partners 
A, For proximity proteomics, PLN was tagged N-terminally with the epitope tag V5 and the ascorbate 
peroxidase APEX2 (APEX2-PLN). APEX2 was separated by a GS linker to enhance flexibility and 
enable PLN protein interactions. As spatial sarcoplasmic reticulum (SR) targeted control, only the PLN 
transmembrane domain was N-terminally tagged by V5 and APEX2 (APEX2-PLNΔ(1-29)). B, APEX2 
expression constructs are located in the SR membrane upon expression, while the PLN cytosolic 
domain and V5-APEX2 face the cytosol. C, Scheme of PLN proximity biotinylation in living cells. APEX2 
generates the biotin-phenoxyl radical (red) and covalently labels proteins in close proximity (<20 nm) 
with biotin (B). Living cells were incubated with 500 µM biotin-phenol (BP) for 30 min, followed by 1 min 




















































4.2.1 APEX2-PLN proximity labeling in HEK293A cells 
To investigate the proximity of PLN by APEX2 proximity labeling, the used APEX2 constructs 
were tested to confirm the correct cellular localization in HEK293A. Therefore, the cells were 
plasmid co-transfected with APEX2-PLN or APEX2-PLN(1-29) and KDEL-Myc expressing 
plasmid used as an endoplasmic reticulum marker. Confocal co-immunofluorescence imaging 




Figure 23 Confocal co-immunofluorescence imaging of APEX2-PLN and APEX2-PLNΔ(1-29) in 
HEK293A cells 
HEK293A cells were co-transfected with either APEX2-PLN (A) or APEX2-PLNΔ(1-29) (B) and KDEL-
Myc plasmid used as endoplasmic reticulum (ER) marker. After 24 h, samples were prepared and 
stained for co-immunofluorescence with V5 and Myc antibodies. Confocal imaging (Zeiss LSM 880, 























marker (KDEL peptide) in the peripheral ER (asterisk) or the perinuclear ER (arrowhead). Dashed boxes 
indicate areas of magnified views. Scale bars: Confocal microscopy 10 µm; Magnification 1 µm. 
 
To test the catalytic APEX2 activity, plasmid transfected HEK293A cells were treated for 30 
min with 500 µM biotin-phenol at 37 °C and 1 mM H2O2 at room temperature (Figure 24). 
Immunoblots showed induction of biotinylation dependent on APEX2 transfected cells, biotin-
phenol, and H2O2.  Omitting biotin-phenol or H2O2 showed only a few endogenously 
biotinylated proteins.  
 
 
Figure 24 PLN based proximity labeling in transfected HEK293A cells 
HEK293A cells were plasmid transfected with APEX2-PLN or APEX2-PLNΔ(1-29). After 24 h of 
expression, proximity labeling was initiated in living cells with 500 µM biotin-phenol (BP) for 30 min, 
followed by 1 mM H2O2 for 1 min. Biotinylated proteins were visualized by immunoblotting using 
streptavidin IRDye 680RD. Transfection controls (Ø) and omitting BP or H2O2 (-) show only endogenous 
biotinylated proteins. V5 antibody shows the expression of APEX2 constructs, GAPDH was used as a 
loading control. 
 
Next, we tested the enrichment of biotinylated proteins by affinity purification using avidin-
agarose beads. Varying the elution conditions using biotin and SDS119 for different incubation 
times and temperatures, we found the elution with 2 mM biotin and 2% SDS for 15 min at RT 
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In general, APEX2-PLN and APEX2-PLN∆(1-29) plasmid constructs could be expressed 
transiently in HEK293A cells. They were localized to the ER as expected and APEX2 was 
functionally active shown by the biotinylation reaction. The enrichment of biotinylated proteins 
was achieved by established protocols. 
 
 
Figure 25 Affinity purification optimization of biotinylated proteins after proximity labeling in 
HEK293A 
E1: 2 mM biotin, 30 min RT
E2: 2 mM biotin, 2% SDS, 15 min RT + 15 min 97 °C
E3: 30 mM biotin, 30 min RT
E4: 30 mM biotin, 2% SDS, 15 min RT + 15 min 97 °C
E2.1: 2 mM biotin, 2% SDS, 30 min RT
E2.2: 2 mM biotin, 2% SDS, 15 min RT + 15 min 70 °C
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APEX2-PLN plasmid transfected HEK293A cells were treated with (+) or without (-) biotin-phenol (BP) 
and H2O2 to induce biotinylation. After cell lysis, biotinylated proteins were enriched by affinity 
purification with monomeric avidin. A, Different elution conditions were used as indicated, and 2 mM 
biotin and 2% SDS (E2) were found to be most efficient. Input (I) and flow-through (FT) were shown 
representative from experiment E1. B, Elution condition E2 was further optimized, testing different 
incubation times and temperatures as indicated. Input and flow through were shown representative from 
experiment E2.1. Biotinylated proteins were detected by immunoblotting using streptavidin IRDye 
680RD. 
 
4.2.2 Neonatal rat cardiomyocyte cell model 
Since PLN is mostly expressed in the heart28,26, neonatal rat cardiomyocytes (NRCMs) were 
used as a cell model for the PLN targeted APEX2 proximity live labeling. NRCMs were isolated 
fresh from neonatal rat hearts and provide week-long observation periods, spontaneous 
beating, and maturation of the cell population120. To verify the localization of endogenous PLN 
and SERCA2a, NRCMs were labeled for co-immunofluorescence microscopy. PLN and 
SERCA2a showed overlapping signals with a reticular structure, whereas PLN showed 





Figure 26 Confocal co-immunofluorescence imaging of endogenous PLN and SERCA2a in 
NRCMs 
NRCMs were prepared for co-immunofluorescence staining after six days of cultivation. Confocal co-
immunofluorescence imaging showed robust expression of PLN and SERCA2a and overlapping signals 
in reticular structures (asterisk). Additionally, PLN showed enriched signals in the perinuclear envelope 
independent of SERCA2a (arrowhead). Dashed boxes indicate areas of magnified views. Scale bars: 
Confocal microscopy 10 µm; Magnification 1 µm. 
 
First, plasmid transfections using Lipofectamine 3000 were tested to target the APEX2 
constructs for expression in NRCMs. Co-immunofluorescence imaging of V5 and endogenous 
SERCA2a showed peripheral SR localizations for both constructs confirming the expected ER 














Figure 27 Confocal co-immunofluorescence imaging of APEX2-PLN and APEX2-PLNΔ(1-29) in 
NRCMs 
Six days after cultivation, primary NRCMs were plasmid transfected with APEX2-PLN or APEX2-
PLNΔ(1-29). After 24 h of expression, confocal co-immunofluorescence imaging showed construct 
expression of APEX2-PLN (A) and APEX2-PLNΔ(1-29) (B). Co-localization with SERCA2a identified a 
peripheral SR localization (arrowheads). Asterisks show un-transfected cells without V5 signal proofing 
antibody specificity. Dashed boxes indicate areas of magnified views. Scale bars: Confocal microscopy 
10 µm; Magnification 1 µm. 
 
Furthermore, the catalytic APEX2 activity in plasmid transfected NRCMs was tested. NRCMs 
were treated with BP and H2O2 and showed induced biotinylation of proteins detected by 
labeled streptavidin in immunoblot (Figure 28A). Additionally, V5 signals show oligomeric 
bands >250 kDa (Figure 28B). 
Taken together, APEX2-PLN and APEX2-PLN∆(1-29) plasmid constructs could also be 
expressed transiently in NRCMs. The APEX2 proteins were localized to the SR similar to the 






















proteins. Important to note is that the transfection efficiency using lipofectamine was very low 
(1-2%) in NRCMs compared to HEK293A cells (data not shown). 
 
 
Figure 28 PLN specific proximity labeling in plasmid transfected NRCMs 
NRCMs were plasmid transfected with APEX2-PLNΔ(1-29) or APEX2-PLN. After 24 h of expression, 
living cells were treated with (+) or without (-) 500 µM biotin-phenol (BP) and 1 mM H2O2 to induce 
biotinylation. Immunoblot showed biotinylated proteins by streptavidin IRDye 680RD (A) and V5 
antibody expression of APEX2 constructs (B) on the same blot. Omitting BP shows only endogenous 
biotinylated proteins. V5 tagged APEX2 constructs show monomeric and oligomeric signals (>250 kDa). 
 
4.2.3 Ratiometric proximity proteomics in NRCMs 
In order to identify quantitatively enriched proteins labeled in the proximity of PLN, the use of 
a ratiometric labeling strategy was desirable. For this kind of experiment, the stable isotope 
labeling of amino acids in cell culture (SILAC) is often used as a ‘gold standard’123,68,54. As 
Feger et al. reported, NRCMs were SILAC labeled previously for five days, resulting in an 
isotope abundance of ~40%124. To test the timescale until 95% of the proteins are SILAC 
labeled in primary isolated NRCMs, cells were cultivated up to 20 days in radiolabeled amino 
acids containing medium. NRCMs were lysed at different time points, trypsin digested, and 
subjected to mass spectrometry. Incorporation of at least 95% of labeled arginine and lysine 
was achieved after 13 days of cultivation (Figure 29A). Parallel immunoblot experiments 

























































days (Figure 29B). This experiment was carried out together with Jonas Peper (Department of 
Cardiology and Pneumology, University Medical Center Göttingen). 
Due to decreased protein expression of PLN and SERCA2a during cultivation, the earliest time 
point of sufficient SILAC incorporation was chosen, namely 13 days. 
 
 
Figure 29 Stable isotope labeling of amino acids in cell culture (SILAC) incorporation in NRCMs 
NRCMs were cultivated over 20 days in medium containing radiolabeled L-arginine (Arg-6) and L-lysine 
(Lys-4) and harvested at the indicated time points. A, Mass spectrometry (LC-MS/MS) quantified 
incorporation of >95% after 13 days of cultivation (red line). n=1. B, Immunoblot analysis showed a 
decreased protein expression of PLN and SERCA2a over the cultivation period.  
 
4.2.4 Adenoviral transduction for proximity labeling in NRCMs 
To achieve a sufficient expression of APEX2-PLN and APEX2-PLN(1-29) for proximity 
labeling in NRCMs, APEX2-PLN and APEX2-PLN(1-29) constructs were cloned into 
adenoviral expression plasmids for the generation of adenoviral particles (serotype V; Ad5) 
(Figure 5). Adenoviral particles were custom made by Sirion Biotech (Martinsried, Germany). 
In order to test the expression and the optimal ratio of adenoviral particles per cell, different 
concentrations of adenoviral particles were tested, namely multiplicity of infection (MOI). After 
48 h of adenoviral expression, fluorescence imaging showed increased eGFP signals, 
whereas, at MOI 100, the signal dropped due to increased cell death (Figure 30A). Also, eGFP 
mRNA levels and protein levels show increased expression with increasing MOI (Figure 
30B,C). Importantly, levels of mRNA and protein expression between APEX2 constructs were 
comparable, allowing the same MOI for transduction. The MOI of 10 was detected as the 
highest least cytotoxic concentration of adenoviral particles determined by microscopy (data 
not shown). 
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Figure 30 Analysis of adenoviral particle concentrations for NRCM transduction 
NRCMs were transduced for 48 h with different concentrations of adenoviral particles (multiplicity of 
infection, MOI) to determine the optimal APEX2-PLN and APEX2-PLNΔ(1-29) expression. A, 
Fluorescence microscopy monitored eGFP marker protein expression increased with the viral particle 
concentration (5x objective, AxioVert Zeiss). MOI 100 showed lower eGFP signals due to increased cell 
death. Scale bar: 500 µm. B, qRT-PCR experiments determined equal eGFP mRNA expression levels 
using same adenoviral concentration in APEX2-PLN and APEX2-PLNΔ(1-29) transduced NRCMs. C, 
Immunoblots showed increased protein expression of V5-APEX2 constructs and eGFP with increasing 
MOI of adenoviral transduced NRCM lysates. α-actinin was used as a loading control. 
 
Additionally, confocal co-immunofluorescence imaging confirmed APEX2 construct protein 
expression in the same cellular compartment as SERCA2a after adenoviral transduction in 
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To summarize, adenoviral constructs for APEX2-PLN and APEX2-PLN∆(1-29) were 
successfully targeted into NRCMs and optimized for transduction. Confocal microscopy 
showed cellular localization similar to SERCA2a signals. 
 
 
Figure 31 Confocal co-immunofluorescence imaging of adenoviral APEX2-PLN and APEX2-
PLN∆(1-29) expression in NRCMs 
NRCMs were cultured for 15 days and transduced with Ad5-APEX2-PLN or Ad5-APEX2-PLN∆(1-29) 
with MOI 10 for 48 h. Cells were fixed, and adenoviral APEX2 constructs were co-stained for V5 (red) 
and SERCA2a (green). Confocal microscopy showed a striated distribution of APEX2 constructs and 
partial overlap with SERCA2a signals (arrowheads). Dashed boxes indicate areas of magnified views. 










4.2.5 PLN specific ratiometric APEX2 proximity labeling in NRCMs 
For the final experiment, NRCMs were cultivated in total for 15 days in radiolabeled amino 
acids containing medium, including two days of adenoviral expression using MOI 10 (Figure 
32A). After induced biotinylation, APEX2 transduced NRCMs showed increased biotinylation 
of proteins, whereas the transduction control eGFP showed only endogenously biotinylated 
proteins (Figure 32B). V5 signals showed a similar expression for both APEX2 proteins. 
 
 
Figure 32 PLN targeted APEX2 proximity labeling in NRCMs for ratiometric proteomics 
A, Experimental time scale for ratiometric APEX2 proximity labeling in APEX2-PLN versus APEX2-
PLNΔ(1-29) transfected NRCMs. B, Immunoblot analysis showed APEX2 dependent biotinylation of 
proteins upon biotin-phenol and H2O2 treatment. V5 antibody from the same blot showed equal 
expression of APEX2-PLN and APEX2-PLNΔ(1-29) proteins. n=5. 
 
For ratiometric proteomics, a three-state SILAC experiment was designed. To exclude effects 
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experiments were performed of which three experiments were performed in parallel (technical 
replicates; labeling I, II, and III), followed by two independent experiments (biological 
replicates, labeling II and III). After the proximity labeling in transduced NRCMs, lysates were 
tested by mass spectrometry for the incorporation of labeled amino acids resulting in a 
minimum of 96.5% incorporation. Next, lysates from each experiment were mixed in a ratio of 
1:1:1, and biotinylated proteins were enriched by avidin affinity purification (Figure 33C). The 
elution fraction of all five experiments was analyzed by ratiometric mass spectrometry (LC-
MS/MS). 
Taken together, isolated NRCMs were successfully radiolabeled and transduced by 
adenoviruses for five experiments. PLN specific APEX2 proximity labeling was performed in 






Figure 33 Ratiometric SILAC APEX2 proximity proteomics in NRCMs 
A, Workflow for quantitative protein radiolabeling in NRCMs by three-state SILAC experiments with 
systematic label switch. Light: Arg-0 and Lys-0; Medium: Arg-6 and Lys-4 ; Heavy: Arg-10 and Lys-8. 
Adenoviral transduction of NRCMs with APEX2-PLN, APEX2-PLNΔ(1-29), and eGFP was followed by 
APEX2 proximity labeling and cell lysis. After mixing lysates in a ratio of 1:1:1, biotinylated proteins were 
enriched using avidin beads and analyzed by mass spectrometry (LC-MS/MS). n=5 (technical replicates: 
I, II, III; biological replicates with the same labeling scheme: II, III). B, Mass spectrometry (LC-MS/MS) 
quantified >96.5% L-arginine (Arg) and L-lysine (Lys) incorporation (red line, 95%). Of note, the scale 
starts at 0.90. C, Lysates of radiolabeled and adenoviral transduced NRCMs were mixed in a ratio of 
1:1:1 after induced biotinylation. Immunoblot showed enrichment of biotinylated proteins after affinity 
purification. The elution fractions of all five experiments were analysed by ratiometric mass 
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4.2.6 Analysis of ratiometric PLN targeted APEX2 proteomic data 
Mass spectrometry data were normalized, and ratios of the individually labeled experiments 
were calculated by MaxQuant software. Logarithmic base 2 (log2) was used as a ratiometric 
value. Resulted ratios of 0 (1:1) were APEX2-PLN enriched over the controls APEX2-
PLN(1-29) or eGFP. For data analysis, only proteins detected in all five experiments were 
used (765 proteins). To demonstrate the enrichment of biotinylated proteins for APEX2-PLN, 
histograms were plotted for log2 ratios of APEX2-PLN / eGFP and APEX2-PLN∆(1-29) versus 






Figure 34 Analysis of ratiometric PLN targeted APEX2 proteomic data 
Histograms of normalized log2 ratios APEX2-PLN / eGFP and APEX2-PLN / APEX2-PLNΔ(1-29) plotted 
against the number of proteins for all experimental replicates with systematic label switch (H, heavy; M, 
medium; L, light). Histograms show broad right-shifted distribution for log2 ratios >0. Proteins identified 
in all five experiments (technical and biological replicates) were analyzed (765 proteins). Bin size = 0.1. 
n=5. 
 









































































































































































































































































































































































































































































































































































































































































































Furthermore, the log2 ratios of 765 detected proteins were plotted against their total intensity 
(Figure 35A,B). PLN was detected on the right end of the distribution (Figure 35A) or isolated 
from the cloud as the most enriched protein (Figure 35B). SERCA2a, a direct PLN interactor, 
was detected as one of the most abundant proteins but showed no significant enrichment (log2 
<0). To assess which proteins were significantly enriched for APEX2-PLN, a statistical z-test 
was performed, testing against 0, and resulted in 133 significantly enriched proteins over 
APEX2-PLN∆(1-29) and eGFP (Figure 35C). Phospholamban was significantly detected in 
both ratios with the highest log2 value. Moreover, PPP1cb and PPP2r1a were identified as 





Figure 35 Protein enrichment after APEX2-PLN proximity labeling in NRCMs 
Average log2 ratios of APEX2-PLN vs. eGFP (A) or APEX2-PLN∆(1-29) (B) plotted against log2 of total 
intensities and show a right-shifted distribution (log2 >0). SERCA2a has been detected as one of the 
most abundant proteins in all samples. C, Log2 ratios of APEX2-PLN vs. APEX2-PLN∆(1-29) or eGFP 
show 765 identified proteins (white points) of which 133 has been significantly enriched for APEX2-PLN 
(blue and orange points). PLN was one of the most enriched proteins. The cytosolic proteins PPP2r1a 
and PPP1cb are known interaction partners of PLN and were significantly enriched by APEX2-PLN. 
 



















































































Gene enrichment analysis of the 133 significantly enriched proteins using the online ToppGene 
Suite tool ToppFun showed significant enrichment of the 14-3-3 protein family (Figure 36A). 
The top six enriched gene families were listed and visualized as data points plotted for log2 





Figure 36 Gene enrichment analysis of APEX2-PLN enriched proteins 
A, APEX2-PLN specific proteins were enriched for their biological functions using ToppGene Suite tool 
ToppFun (default setting: FDR correction, p-value cut off at 0.05 and gene limit set between and 
including 1 and 2000 per pathway). Bar graphs show the top six enriched gene families based on 
APEX2-PLN enriched proteins. Numbers in bar graphs indicate the detected proteins of the group. B, 
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APEX2-PLN significantly enriched proteins were plotted for log2 ratios of APEX2-PLN / APEX2-PLN∆(1-
29) and APEX2-PLN / eGFP. Orange points show the gene family enriched proteins from A. Blue points 






The exploration of novel PLN interaction partners is of high importance to understand how it is 
molecularly regulated and to develop rationales for new therapeutic interventions for patients 
and animals with heart disease. 
This study was designed to identify potential new protein interactions of PLN. A proximity-
based labeling technique for living primary heart cells was developed and combined with a 
quantitative proteomic analysis strategy. For live-cell labeling, the engineered ascorbate 
peroxidase APEX2 was fused N-terminally to PLN. After establishing the expression, 
localization, and functionality in HEK293A cells, neonatal rat cardiomyocytes were used as the 
primary model system. The advantages of this NRCM based proteomic labeling system are 
culture conditions that provide week-long observation periods and spontaneous beating and 
maturation of the cell population120. Additionally, NRCMs can be targeted by DNA vectors for 
genetic modifications as described previously by others120,126,127. Furthermore, a high degree 
of incorporation of stable isotope-labeled amino acids in cell culture (SILAC) was established 
for NRCMs. Hence, a ratiometric proteomic analysis was used after PLN targeted APEX2 
proximity labeling in living cells. Targeting the cells with adenoviral vectors was used for 
efficient transduction. The ratiometric APEX2 proximity labeling in NRCMs identified proteins 
in nanometric proximity to PLN. In particular, 14-3-3 protein isoforms were identified, which 
function as phosphoadaptor proteins. It was predicted before that PLN contains a target motif 
for 14-3-3128. Hence, we hypothesized that 14-3-3 binding protects phospholamban from 
dephosphorylation, which may prolong the Ca uptake activity by SERCA2a after ß-adrenergic 
stimulation. This interaction was established in collaboration and is now part of a manuscript 
in preparation by Julia Menzel et al. (Prof. Dr. Blanche Schwappach, Department of Molecular 
Biology, University Medical Center, Göttingen). 
 
4.3.1 PLN targeted APEX2 proximity labeling in HEK293A and NRCM 
It has been shown before that PLN can N-terminally be tagged with a biosensor and is localized 
to the SERCA2a compartment129. Based on the same principle, PLN was N-terminally tagged 
with the ascorbate peroxidase APEX2 for the identification of novel interaction partners. 
APEX2 proximity labeling was previously established in several studies to map the 
mitochondrial intermembrane space68, cilia70, or the spatiotemporal proximity of G-protein 
coupled receptors71. Whereas BioID has a biotinylation radius of 10 nm115, APEX2 has a 
proximate radius of <20 nm118 and is described as a reactive cloud with a diffusion gradient. 
Therefore, APEX2 is not only labeling direct interaction partners but additionally proximal 
proteins. APEX2 has a high enzymatic activity and allows for a short labeling time, i.e. a 
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snapshot within 1 min, whereas the labeling with BioID is designed to as a cumulative approach 
to identify interactors over hours66. However, the treatment of cells with hydrogen peroxide, to 
initiate the biotinylation reaction by APEX, can cause oxidative stress130 or altered protein 
interactions131. 
 
4.3.2 APEX2-PLN targeting in neonatal rat cardiomyocytes 
After the APEX2-PLN localization and peroxidase function were successfully established in 
HEK293A cells, NRCMs were used as a primary cardiac cell model. Adult cardiomyocytes 
show typical alterations in morphology under culturing conditions (within hours) and are 
generally reported to be difficult to transfect with non-viral approaches120. The transfection 
efficiency in NRCMs using the calcium-phosphate co-precipitation method, however, is also 
low (1-2%)126. Low transfection efficiency was confirmed for NRCM transfection by confocal 
imaging (data not shown). Therefore, adenoviral vectors were used for efficient gene 
transfer127. In order to achieve abundant expression of APEX2-PLN and APEX2-PLN∆(1-29) 
in NRCMs, recombinant adenoviral vectors (serotype V) were generated and amplified (Sirion 
Biotech, Martinsried). 
 
4.3.3 Quantitative proteomic analysis of NRCMs 
Quantitative proteomic approaches are essential to determine global proteomic changes in 
cells, tissue, or organisms. As Mass spectrometry is not quantitative per se, stable isotope 
labeling by amino acids in cell culture (SILAC) is one relative quantitation method123. SILAC 
uses the incorporation of isotope-labeled amino acids into proteins during cell culturing. 
Therefore, the culture medium is lacking an essential amino acid, which is supplemented with 
the isotope-labeled form instead. Ong and Mann reported complete incorporation in NIH 3T3 
fibroblast after five cell divisions123. Feger et al. used SILAC in NRCMs and reached a relative 
isotope abundance of ~40% after 120 h124. However, no additional data became available 
about the SILAC incorporation in non-proliferating primary NRCMs. Thus, it was systematically 
tested for up to 20 days. That resulted in isotope-labeled amino acid incorporation of over 
>95% after 13 days (Figure 29). Finally, NRCMs were established as a suitable cell model for 
APEX2 proximity labeling combined with quantitative proteomics. 
 
4.3.4 Analysis of ratiometric PLN targeted APEX2 proteomic data 
The calculated log2 ratio of APEX2-PLN enriched proteins against APEX2-PLN∆(1-29) or 
eGFP showed a right-shifted distribution, in particular, values log2  0. As expected, the right 
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shift of both ratios differs and shows for eGFP control a higher spectrum compared to the SR-
targeted control APEX2-PLN∆(1-29). eGFP was used as transduction control and to exclude 
unspecific enrichment of protein interactions due to affinity purification. APEX2-PLN∆(1-29) 
was used to exclude SR resident proteins as false-positive enriched hits. Additionally, 
overlapping interactors for both PLN and PLN∆(1-29) are expected to be biotinylated to the 
same degree and show no enrichment (log2 ratio <0). Therefore, the log2 ratio variance of 
APEX2-PLN over APEX2-PLN∆(1-29) was smaller compared to the log2 ratio variance over 
eGFP. In order to cover all PLN interactions, an additional soluble cytosolic APEX control will 
be applied. Against expectation, SERCA2a, a direct PLN interactor, has been detected but 
was not significantly enriched. That is, while the total abundance for each log2 ratio revealed 
SERCA2a as one of the most abundant proteins in the samples. Here suggests that 
biotinylated SERCA2a proteins get lost in the background signals. 
Nonetheless, previously established interactions were significantly enriched for PLN: PPP1cb 
and PP2r1a. The protein phosphatase 1 catalytic subunit β/δ (PPP1cb) is one of four 
isoforms132 and active as a holoenzyme together with one or more regulatory subunits. PP1 
accounts for 70% of PLN phosphatase activity towards the PKA phosphorylation site Ser-16 
and CamK2 phosphorylation site Thr-1738. Additionally, the protein phosphatase 2A scaffolding 
subunit Aα (PPP2r1a) is one of two constant regulatory subunit isoforms of PP2. Together with 
the catalytic subunit, they form the core enzyme complex133. Moreover, to build the PP2A 
holoenzyme, the core enzyme binds to one out of nine different regulatory subunits, which 
facilitates the targeting to distinct and well defined subcellular localizations133. Compared to 
PP1, the PP2A complex accounts for the remaining 30% of PLN dephosphorylation125. Taken 
together, two phosphatase subunits were correctly labeled in the proximity of PLN in living 
NRCMs, proving the ability of this PLN-based proximity assay to label transient protein 
interactions. 
 
4.3.5 Gene enrichment analysis of APEX2-PLN enriched proteins 
Gene enrichment analysis of 133 significantly enriched proteins revealed several gene 
families. The enriched gene family with the highest p-value was the 14-3-3 protein. 14-3-3 
proteins are phosphoadaptor proteins, of which several isoforms are expressed in the heart. 
Here, six out of seven isoforms were enriched for APEX2-PLN. They bind to proteins that 
contain phosphorylated Ser/Thr residues within specific sequence motifs134,135. Interestingly, 
an Arg-based PLN motif has been predicted as the mechanism of the 14-3-3 protein 
interaction128. The peptide-binding groove of heterodimeric 14-3-3 proteins is highly 
conserved, and all 14-3-3 proteins bind to similar peptide motifs135,136, suggesting that all 
isoforms can bind to PLN. While both PLN and SLN function as inhibitory regulators of 
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SERCA2a in the heart, only PLN is predicted as 14-3-3 target, when Ser-16 or Thr-17 is 
phosphorylated. In order to look at other SERCA2a regulating micropeptides26, another-regulin 
(ALN) was predicted to be a 14-3-3 target when Ser-19 is phosphorylated, together with 
myoregulin (MLN), when Thr-12 is phosphorylated137. That suggests that 14-3-3 interactions 
with SERCA regulating micropeptides are a general mechanism not restricted to the heart. An 
important consequence of 14-3-3 binding to PLN will be a protection from dephosphorylation 
by steric masking, prolonging the increased SERCA2a activity during ß-adrenergic stimulation. 
Next, five out of six peroxiredoxins (Prdx) were significantly enriched through APEX2-PLN 
labeling. Prdxs represent a diverse family of antioxidant and redox signaling proteins and are 
highly expressed in the heart138. They may confer protection against oxidative stress and are 
well known to inhibit apoptosis mediated by hydrogen peroxide139. H2O2 is a substrate of Prdxs 
that catalyze its reduction138. This reaction is also needed for the oxidation of Prdxs to form 
heterodimers through inter- and intramolecular disulfide bonds138. In the context of the APEX2 
proximity labeling initiated with 1 mM H2O2, Prdxs activity may protect other proteins from H2O2. 
Interestingly, Prdxs were enriched over the APEX2-PLN∆(1-29) control. That suggests a 
specific enrichment of Prdx proteins for APEX2-PLN. It has been reported that Prdx oxidation 
was associated with translocation from the cytosol to the membrane and myofilament-enriched 
fractions138. This mechanism may explain the proximity to PLN and the resulting labeling of 
Prdxs upon oxidation. Interestingly, Prdx-II protein expression is increased in PLN knockout 
hearts140, and it is hypothesized that it may serve as a cardioprotective mechanism141. 
Additionally, cardiac-specific overexpression of Prdx-II leads to reduced PLN Ser-16 
phosphorylation, while total PLN protein levels were unchanged142. Hence, it was speculated 
that Prdx-II may regulate cardiac contractility through altered PLN phosphorylation levels142 or 
may play a role for cardiomyocyte apoptosis141.  
Along with 14-3-3 proteins and peroxiredoxins, the group of LIM domain containing proteins 
was enriched for APEX2-PLN. The LIM domain is a specialized double-zinc finger motif 
defining a large protein family. Some are mainly expressed in mammalian hearts playing a 
pivotal role in organizing the cytoskeleton, signal transduction, gene expression, 
cardiomyocyte metabolism, and cell differentiation143. LIM domain proteins are thought to 
function as a protein-protein interaction module, facilitating contacts between proteins of 
functional complexes144. Eight LIM domain containing proteins were enriched by APEX2-PLN. 
Considering established functions of LIM domain containing proteins, they seem to be proximal 
rather than directly bound to PLN. 
Another group enriched for APEX-PLN is the protein family of septins (SEPT). Septins are 
GTP binding proteins involved in cytokinesis and other biological processes, including cell 
polarity, exocytosis, ciliogenesis, phagocytosis, motility, and apoptosis145. Septins can 
assemble into a filamentous protein complex in the cell. They can directly interact with 
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membranes, microfilaments, and microtubles145. In the developing heart, a significant level of 
expression has been found for SEPT2, SEPT6, SEPT7, and SEPT9, whereas no detectable 
expression was found in the adult heart146. Interestingly, the PLN interaction partner HAX-
145,147 was reported to modulate changes in septin signalling148. Due to the loss of SEPT 
expression in the adult heart, there seems to be no physiological role for interactions with PLN 
in adult cardiomyocytes. 
Furthermore, the group of troponin complex subunits was significantly enriched for APEX2-
PLN. The cardiac troponin consists of three subunits149,150, which are troponin C (TnC), 
troponin I (TnI), and troponin T (TnT). All three subunits were labeled in the proximity of PLN. 
TnC is the Ca2+-binding subunit that inhibits the actomyosin interaction, TnI is an inhibitory 
component of contractile interaction, and TnT is a tropomyosin-binding component. All three 
subunits are involved together with myosin, actin, and tropomyosin in the Ca2+-regulated 
physiological muscle contraction151. Interestingly, both PLN92 and TnI152 are targets of PKA in 
ventricular myocytes and are phosphorylated upon ß-adrenergic stimulation. TnI 
phosphorylation increases the Ca2+ dissociation from TnC153 and accelerates muscle 
relaxation, similar to PLN phosphorylation27. Taken together, it appears that troponin and PLN 
are in close proximity rather than direct interactors by sharing the same protein kinase. 
Finally, the family of small heat shock proteins was significantly enriched. Small heat shock 
proteins function as molecular chaperones supporting the assembly, disassembly, 
stabilization, and transport of intracellular proteins154. The small heat shock protein 20 (HSPB6) 
is known to regulate PLN dephosphorylation43. HSPB6 inhibits the enzymatic activity of PP1, 
which was associated with an increased level of PLN phosphorylation and SR Ca2+ transport43. 
This finding confirms again the specificity of the PLN targeted APEX2 proximity assay, 
detecting also secondary interactions. 
In summary, a PLN targeted APEX2 proximity labeling assay was established in NRCMs to 
identify novel candidate interaction partners as a primary hypothesis-generating screen. 
Neonatal cardiomyocytes were cultivated in SILAC medium as a ratiometric proteomic 
approach. Additionally, a protocol for adenoviral NRCM transduction was established. Based 
on three technical and two biological replicates, 133 proteins were significantly enriched 
following APEX2-PLN labeling in living NRCMs. Among these hits, several protein families 
have been identified with 14-3-3 proteins as the most significant interaction candidates. 
Overall, APEX2 proximity labeling was used as a screening tool and combined with additional 
methods to confirm and study protein-protein interactions. Furthermore, it will be of high 
interest, which physiological consequences PLN mutations like R14del or R9C will have on 




5 Conclusion and Outlook 
 
 
This study aimed to identify previously unknown PLN protein interactions by using two different 
unbiased proteomic approaches. First, the complexome profiling analysis of isolated 
ventricular cardiomyocyte membranes was established and showed known and previously 
unknown multi-protein complexes. Mitochondrial OXPHOS complexes were used for quality 
control, and their assembly into supercomplexes could be observed. The Na,K-ATPase was 
captured in two different states, with and without its regulator phospholemman. Additionally, 
we could show that PLN and SERCA2a are highly associated and are associated with 
macromolecular complexes. Importantly, at higher molecular weight, a novel SR Ca2+ cycling 
complex comprised of the RyR2 calcium release channel, SERCA2a, and each regulatory 
protein subunits, was identified. This finding was part of the published manuscript by Alsina et 
al., showing that the regulatory subunit PPP1R3A targets PP1 not only to PLN but also to the 
RyR2 channels and is part of the SR Ca2+ cycling complex. Interestingly, this complex was 
altered in PLN-deficient mice showing the abundance of PLN as an important mediator.  
Furthermore, hierarchical cluster analysis revealed SR localized SLMAP as a potential 
interactor of PLN. It was shown that SLMAP is localized adjacent to PLN in mouse VCM by 
STED microscopy and could be co-eluted with PLN by affinity purification. Remarkably, as 
proteins involved in Ca2+ handling are downregulated during the progression of heart failure, 
SLMAP showed increased protein expression in mice four weeks after TAC surgery. Also, 
PLN-deficient mice showed higher abundance in high molecular weight complexes compared 
to WT and increased protein expression of SLMAP. Also, during differentiation and maturation 
of human iPSC towards a cardiac phenotype, SLMAP protein expression increases. This 
suggests an important role of SLMAP during heart differentiation and remodeling. 
Moreover, PLN targeted APEX2 proximity labeling was established in living NRCMs and gave 
further insights into the interactome of PLN. Gene enrichment analysis identified several 
proteins and gene families, which were specifically labeled in the proximity of PLN. Six of seven 
14-3-3 proteins were significantly enriched in the proximity of PLN, together with 
peroxiredoxins, Lim domain containing proteins, septins, troponin complex subunits, and small 





In summary, two different proteomic approaches revealed previously unknown PLN protein 
interactions, providing new insights into the interactome of PLN. The identified interactors will 
be subject to future studies to elucidate their functional role in health and disease. This will 
provide the development of rationales for new therapeutic interventions for patients and 
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Sptan1 1.57 0.78 2.14E-03 1.12E-03 
25 P23693 Troponin I, cardiac muscle Tnni3 2.83 0.60 1.51E-28 1.20E-03 
26 Q9Z2J4 Nexilin Nexn 1.45 0.56 9.86E-10 1.38E-03 
27 A2RUW1 Toll-interacting protein Tollip 1.71 0.53 2.30E-03 1.46E-03 
28 P68255 14-3-3 protein theta Ywhaq 2.37 0.54 4.76E-30 1.68E-03 
29 G3V7Q7 
IQ motif containing GTPase 
activating protein 1 (Predicted) 
Iqgap1 1.97 0.62 8.17E-04 1.87E-03 




Peroxiredoxin-1 Prdx1 2.31 0.31 1.35E-25 2.04E-03 
32 B2GVB4 Septin-9 Sept9 1.28 1.01 2.93E-10 2.20E-03 
33 F1LMC7 Septin-7 Sept7 2.48 0.74 5.90E-15 2.27E-03 
34 P97541 Heat shock protein beta-6 Hspb6 1.25 0.47 1.90E-03 2.45E-03 
35 Q4G079 
Aminoacyl tRNA synthetase 
complex-interacting 
multifunctional protein 1 
Aimp1 1.80 0.25 5.57E-12 2.60E-03 




LIM domain 7 Lmo7 1.45 0.29 3.88E-03 2.92E-03 












41 P63102 14-3-3 protein zeta/delta Ywhaz 1.78 0.44 7.56E-36 3.76E-03 
42 Q2IBC6 Caveolin Cav1 1.49 0.38 9.82E-05 3.97E-03 
43 P62142 
Serine/threonine-protein 
phosphatase PP1-beta catalytic 
subunit 
Ppp1cb 0.80 0.26 1.42E-07 4.03E-03 




Rars 1.05 0.30 6.81E-06 4.33E-03 










Actin-related protein 3 Actr3 1.38 0.25 1.45E-24 4.66E-03 
49 P68511 14-3-3 protein eta Ywhah 1.41 0.45 7.52E-11 5.05E-03 
50 Q9ESH1 26S proteasome subunit S5a Psmd4 0.90 0.10 4.79E-03 5.06E-03 
51 O35878 Heat shock protein beta-2 Hspb2 2.17 0.22 2.28E-27 5.31E-03 
52 Q6T487 Alpha-actinin-1 Actn1 1.07 0.54 1.44E-09 5.46E-03 
53 P62963 Profilin-1 Pfn1 1.70 0.37 3.63E-11 5.48E-03 
54 Q99MZ8 LIM and SH3 domain protein 1 Lasp1 1.43 0.67 4.56E-09 5.70E-03 
55 P85515 Alpha-centractin Actr1a 0.98 0.16 2.41E-06 5.73E-03 
56 P62260 14-3-3 protein epsilon Ywhae 1.81 0.40 1.29E-19 5.90E-03 
57 B4F761 Monocarboxylate transporter 4 Slc16a3 0.72 0.28 1.17E-09 5.90E-03 
58 P52944 PDZ and LIM domain protein 1 Pdlim1 2.13 0.45 3.25E-11 6.05E-03 




Aldoa 3.19 0.62 2.62E-08 6.28E-03 








Peroxiredoxin-2 Prdx2 2.61 0.23 1.67E-25 6.80E-03 




Usp5 1.10 0.33 2.05E-06 7.12E-03 
66 P38983 40S ribosomal protein SA Rpsa 1.06 0.16 3.73E-03 7.27E-03 
67 P61983 14-3-3 protein gamma Ywhag 1.75 0.40 1.57E-13 7.74E-03 
68 Q5XI34 
Protein phosphatase 2 (Formerly 
2A), regulatory subunit A (PR 65), 
alpha isoform 




Cap2 1.57 0.32 1.36E-36 8.36E-03 
70 Q66H61 Glutamine--tRNA ligase 
RGD156
2301 
0.99 0.08 6.67E-12 8.57E-03 
71 Q91Y81 Septin-2 Sept2 1.46 0.69 1.81E-06 8.94E-03 
72 Q5RKI5 FLII, actin-remodeling protein Flii 1.65 0.28 1.95E-02 9.23E-03 
73 Q32PX2 
Aminoacyl tRNA synthase 
complex-interacting 
multifunctional protein 2 
Aimp2 1.84 0.22 3.03E-31 9.26E-03 
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Peroxiredoxin-5, mitochondrial Prdx5 2.50 0.22 3.10E-11 9.73E-03 
76 Q99J82 Integrin-linked protein kinase Ilk 2.11 0.46 3.10E-20 1.02E-02 




Prdx3 1.26 0.39 1.14E-07 1.13E-02 




80 P14668 Annexin A5 Anxa5 2.62 0.64 3.32E-13 1.23E-02 
81 P97536 
Cullin-associated NEDD8-
dissociated protein 1 
Cand1 0.66 0.35 4.69E-03 1.27E-02 




Programmed cell death 6-
interacting protein 
Pdcd6ip 1.04 0.19 1.33E-05 1.31E-02 
84 Q6AYF2 LIM and cysteine-rich domains 1 Lmcd1 1.19 0.45 1.59E-14 1.36E-02 
85 G3V852 
RCG55135, isoform CRA_b 
(Talin 1) 
Tln1 2.19 0.44 7.25E-04 1.42E-02 
86 F1LZX9 Integrin subunit alpha V Itgav 1.55 0.58 8.32E-08 1.45E-02 
87 R9PXU3 
Protein kinase C and casein 
kinase substrate in neurons 2 
protein 
Pacsin2 1.62 0.50 2.22E-12 1.53E-02 
88 D4A7U1 Zyxin Zyx 1.66 0.54 2.57E-23 1.63E-02 
89 Q5VLR5 BWK4 Erp44 0.88 0.27 1.01E-05 1.84E-02 
90 Q6RUV5 
Ras-related C3 botulinum toxin 
substrate 1 
Rac1 0.56 0.21 3.86E-14 1.93E-02 
91 P31399 
ATP synthase subunit d, 
mitochondrial 
Atp5h 1.46 0.43 3.11E-06 1.96E-02 
92 Q5XIM9 T-complex protein 1 subunit beta Cct2 1.27 0.42 2.17E-38 1.98E-02 
93 Q9Z270 
Vesicle-associated membrane 
protein-associated protein A 
Vapa 1.91 0.13 3.02E-25 2.10E-02 
94 D3ZZZ9 
Catenin (Cadherin associated 
protein), delta 1 (Predicted) 
Ctnnd1 0.68 0.45 3.74E-02 2.11E-02 
95 B0BNA7 
Eukaryotic translation initiation 
factor 3 subunit I 
Eif3i 0.84 0.24 1.84E-03 2.19E-02 
96 G3V6S0 Spectrin beta chain Sptbn1 2.20 0.69 3.00E-05 2.31E-02 
97 M0R3V7 Sodium/calcium exchanger 1 Slc8a1 1.15 0.77 4.29E-04 2.40E-02 






Ankyrin-3 Ank3 1.46 0.48 8.05E-03 2.50E-02 
100 P63259 Actin, cytoplasmic 2 Actg1 1.09 0.34 2.32E-06 2.54E-02 
101 Q4FZT9 
26S proteasome non-ATPase 
regulatory subunit 2 
Psmd2 0.75 0.16 8.12E-09 2.59E-02 
102 D4A6X1 Dysferlin (Predicted) Dysf 1.48 0.26 2.29E-03 2.63E-02 
103 D3ZRX9 Calponin Cnn2 1.43 0.42 7.59E-06 2.65E-02 




Filamin-C Flnc 2.33 0.19 1.07E-03 2.87E-02 
106 Q9QZA6 CD151 antigen Cd151 1.92 0.25 2.78E-06 2.90E-02 
107 P52555 
Endoplasmic reticulum resident 
protein 29 
Erp29 0.65 0.38 3.24E-05 2.94E-02 
108 P60711 Actin, cytoplasmic 1 Actb 1.24 0.34 9.18E-15 2.97E-02 
109 D4ACB8 
Chaperonin subunit 8 (Theta) 
(Predicted) 
Cct8 1.50 0.11 2.51E-39 3.00E-02 




Transcriptional activator protein 
Pur-beta 
Purb 1.16 0.15 1.00E-11 3.32E-02 
112 P26772 
10 kDa heat shock protein, 
mitochondrial 
Hspe1 2.58 1.24 5.27E-07 3.40E-02 
113 R9PXU6 Vinculin Vcl 1.55 0.31 1.10E-02 3.43E-02 




Actin-related protein 2/3 complex 
subunit 2 






Rpn1 0.35 0.14 4.28E-02 3.76E-02 








PDZ and LIM domain protein 3 Pdlim3 2.51 0.36 7.04E-07 3.92E-02 
120 G3V6S3 Calumenin Calu 0.60 0.23 1.09E-02 3.93E-02 
121 G3V7Y3 
ATP synthase subunit delta, 
mitochondrial 
Atp5d 0.43 0.60 1.76E-02 3.99E-02 
122 Q9ESN0 Protein Niban Fam129a 0.68 0.27 9.99E-03 4.10E-02 
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Fh 0.52 0.34 1.74E-02 4.17E-02 
125 D3ZG43 
NADH dehydrogenase 
(Ubiquinone) Fe-S protein 3 
(Predicted) 






Ugp2 1.81 0.29 1.99E-57 4.29E-02 
127 Q6AYD5 
Eukaryotic peptide chain release 
factor GTP-binding subunit 
ERF3B-like 




Acsl1 0.42 0.34 4.69E-02 4.50E-02 
129 G3V8A5 
Vacuolar protein sorting-
associated protein 35 
Vps35 0.48 0.35 1.52E-06 4.70E-02 
130 P82995 Heat shock protein HSP 90-alpha 
Hsp90aa
1 
1.07 0.21 2.55E-38 4.77E-02 
131 Q6IMZ3 Annexin Anxa6 2.81 0.29 2.95E-08 4.81E-02 
132 Q07009 Calpain-2 catalytic subunit Capn2 0.93 0.25 1.78E-06 4.92E-02 
133 Q63362 
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 5 






Table 10 Gene family enriched proteins after PLN targeted APEX2 proximity labeling in NRCM 


























28 P68255 14-3-3 protein theta Ywhaq 2.37 0.54 4.76E-30 1.68E-03 
41 P63102 14-3-3 protein zeta/delta Ywhaz 1.78 0.44 7.56E-36 3.76E-03 
49 P68511 14-3-3 protein eta Ywhah 1.41 0.45 7.52E-11 5.05E-03 
56 P62260 14-3-3 protein epsilon Ywhae 1.81 0.40 1.29E-19 5.90E-03 
67 P61983 14-3-3 protein gamma Ywhag 1.75 0.40 1.57E-13 7.74E-03 
110 Q5EBB0 14-3-3 sigma Sfn 2.33 0.65 1.16E-06 3.27E-02 
        





























Peroxiredoxin-1 Prdx1 2.31 0.31 1.35E-25 2.04E-03 
















        



























Cysteine and glycine-rich protein 
3 
Csrp3 2.34 0.40 4.22E-29 2.30E-04 
22 P47875 
Cysteine and glycine-rich protein 
1 




LIM domain 7 Lmo7 1.45 0.29 3.88E-03 2.92E-03 
54 Q99MZ8 LIM and SH3 domain protein 1 Lasp1 1.43 0.67 4.56E-09 5.70E-03 
58 P52944 PDZ and LIM domain protein 1 Pdlim1 2.13 0.45 3.25E-11 6.05E-03 
84 Q6AYF2 LIM and cysteine-rich domains 1 Lmcd1 1.19 0.45 1.59E-14 1.36E-02 




PDZ and LIM domain protein 3 Pdlim3 2.51 0.36 7.04E-07 3.92E-02 
        


























32 B2GVB4 Septin-9 Sept9 1.2837 1.0102 2.93E-10 2.20E-03 




Septin-11 Sept11 0.9675 0.8788 3.92E-02 3.53E-03 




        


























25 P23693 Troponin I, cardiac muscle Tnni3 2.83 0.60 1.51E-28 1.20E-03 
59 Q4PP99 Cardiac troponin C Tnnc1 1.82 0.30 8.99E-06 6.19E-03 





Catenin (Cadherin associated 
protein), delta 1 (Predicted) 
Ctnnd1 0.68 0.45 3.74E-02 2.11E-02 
        


























9 G3V913 Heat shock protein beta-1 Hspb1 1.28 0.22 6.10E-23 2.97E-05 
34 P97541 Heat shock protein beta-6 Hspb6 1.25 0.47 1.90E-03 2.45E-03 
51 O35878 Heat shock protein beta-2 Hspb2 2.17 0.22 2.28E-27 5.31E-03 
 
 
 
